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Abstract: 
Purpose: The global financial crisis of 2008, considered by many economists to have been the most 
consequential since the great depression of the 1930s, altered the very fabric of global macro-economy and left 
many short and long-term impressions at various levels. Though the catastrophic effect of that meltdown 
penetrated the global market with lightning speed, the aftermath was rather uneven in its manifestation. 
Countries of American and European continent suffered severely but Asian countries were rather mildly affected 
and the reason behind this uneven perfusion could be the disparity in the economic environment at the 
microeconomic and macroeconomic levels in different continents. 
The Purpose of carrying out this research is to unveil the influence of internal microeconomic factors at firm 
level as well as external macroeconomic factors at country level on the overall stock price of Pharmaceutical 
companies of Asia's emerging market (India) and emerged markets of United States of America and Western 
European countries (Germany, France, UK, and Switzerland) after the global financial crisis of year 2008. 
Research Design/Methodology: During the present course of the investigation, secondary data of forty 
pharmaceutical companies from the year 2008 to the year 2017 has been employed to perform an empirical 
analysis. Moreover, an explanatory and comparative research design has been applied to corroborate the 
statistical outcome. 
For statistical analysis, EViews 10 student version, statistical software has been used on the dependent variable 
"Organization Stock Price" and several internal independent variables such as Return on Equity (ROE), Earnings 
Per Share (EPS), Dividend Per Share (DPS), Dividend Payout Ratio (DPR), PE ratio, firm's asset as well as few 
macroeconomic level independent variables such as corporate tax, inflation rate, GDP and exchange rate. 
Findings: Price movement of stocks is not independent in nature and doesn't follow a random walk. There are 
several factors responsible for the stock price movement such as investor sentiment, social, economic, 
environment and organization's operational and financial situation etc. This study shows how the aforementioned 
factors affect the stock prices of sample companies of emerging and emerged markets. 
Practical Implications: The outcome of this research could be helpful to managers to regulate organization's 
financial ratios and address the macroeconomic fluctuations to sustain the momentum of the stock price that will 
inadvertently increase the value of the company. From the investor's point of view, this study could provide them 
with better anticipation of future trends in the stock prices. 
Originality/Value: This study offers a contemporary review of the role of organizational and macroeconomic 
factors on the share price of companies and the stock market, thus contributes to the available literature in this 
domain. 
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1. Introduction 
The year 2008 brought about successive quarters of negative growth in the gross domestic product 
(GDP) of countries across the continents and had a damaging effect on the industries because economic 
downturns directly triggered a strong decline in the performance of various macroeconomic Key Performance 
Indicators (KPIs). Against that grim backdrop, global pharmaceutical industry fared better as they were not 
dangerously reliant on borrowing and therefore less exposed to the macro environment (Law, 2008). Although 
the pharmaceutical industry has always had its own share of problems, crash of 2008 had got two things going 
for them: they became more attractive for investors and unsettled times raised the demand for medicines. On the 
other hand, lack of global spending from governments and disparity in public medicines coverage inadvertently 
pushed the Pharmaceutical industry to uncharted territories. 
To thrive and excel in the testing times, pharmaceutical companies have come under great pressure to 
increase the efficiency and effectiveness of their operations. A looming patent cliff, with approximately 40% of 
the top-selling products worldwide going out of patent, has been resulting in companies losing their patents with 
the substantial impact of the revenue. There is also a consolidation of providers (doctors, group practices, 
hospitals, health systems) into larger accounts that have greater influence and economies of scale. Healthcare 
reform, driven by government policy, is reshaping the delivery of healthcare, from care coordination to 
reimbursement strategies, impacting behaviours and tactics within the marketplace (O’riordan et. al., 2016). 
Tightening regulations and ballooning healthcare cost have also impacted the healthcare operating models, 
reflecting the major shift in marketing tactics and customer engagement to reporting requirements by the 
government, payers, and providers. 
Amidst the mounting pressure coming from the aforementioned fronts, the fundamentals of the 
pharmaceutical industry have remained strong. The output of new drugs has been increasing and looks set to 
remain elevated over the next five years, largely based on the exciting new science of speciality medicines, to 
offset current and future patent expiries. After four years of falling or stagnating revenue from the year 2011to 
year 2014, the industry returned to growth in year 2015 with acceleration and improved operating margins in the 
year 2016. But, the new science of speciality medicines faces a persistent affordability gap between payers and 
governments budgets and the sales forecasts for new products. Some notable, recent new launches have been 
struggling to perform on account of concerns over the prevailing price sensitive climate. The key impact of 
accelerating revenue growth and improving operating margins, despite falling profit margins, on investors has 
been profound. The shift to speciality drugs, backed by strong pipeline, has opened up avenues to investors 
worldwide to favour stocks backed by value driven companies with focus on personalized patient outcomes by 
leveraging technology collaboration and driving operational efficiency. Aftermath of the year 2008 meltdown 
was momentum-driven move to the downside soaked in pessimism and massive liquidity crunch. 
The stock price is the primary indicator for investors to gauge the financial health of institutions. Listed 
institutions deploy their shares in the market to collect more funds to expand the business, unlike unlisted 
companies, who follow the Initial Public Offering (IPO) process. Moreover, stock price directly correlates with 
the amount of assets that the institution owns after the shareholder invests in the business, so this value is 
incurred on the balance sheet by the asset (Uddin, 2009). At firm-specific level, a bullish trend in the stock price 
of the firm reflects the confidence of investors in the fundamentals and performance of the firm and a bearish 
trend in the stock price of the firm reflects low confidence of investors in the fundamentals and performance of 
the firm. At the macroeconomic level, consumer prices, industrial production, exchange rate and the market rate 
of interest reflect bidirectional causation with stock prices affecting companies in both the short and long term. 
From the standpoint of financial experts and economist, there are many firm level and macroeconomic 
factors, play a pivotal role in the firm's financial and business operations differently and eventually drive the 
stock price. It is important to take into consideration that macroeconomic factors are more decisive in their 
impact on the oscillation of many firm-level factors controlling the stock rally. Therefore, the overall impact of 
the aforementioned factors varies, depending on the nature of business and industry in which firms operate. 
Basically, there are two types of industries, based on their sensitivity towards fluctuation in the economic cycle: 
 Cyclical Industries: Cyclical Industries and their stocks adhere tightly to the economic cycle. During the 
ascending economic phase, their stocks perform above average. However, during the descending 
economic phase, they get dipped into a downward direction. Example of cyclical industries such as 
automobile, Information technology, steel, tourism, fashion and so on. 
European Journal of Business and Management                                                                                                                               www.iiste.org 
ISSN 2222-1905 (Paper) ISSN 2222-2839 (Online) 
Vol.11, No.36, 2019 
 
164 
 Non-Cyclical Industries: Since non-cyclical industries manufacture and distribute goods and services, 
which are always required for society such as food, power, medicine, and other utilities, their stocks do 
not tightly attached with the economic cycle. As a result, they tend to perform rather neutrally during 
both the ascending and descending phases of the economic cycle. 
Since medicines are one of the most basic needs for human being and animals to treat diseases and maintain 
a healthy life and pharmaceutical sector manufactures medicines to cater to this need of the global population, 
this industry is considered as a non-cyclical industry by economists and financial experts. 
The main objectives of this study to investigate the collective and individual effects of internal 
microeconomic factors and external macroeconomic factors on the market stock price of Pharmaceutical 
companies in emerging and emerged markets. In case of India: most of the Indian companies had positive net 
income throughout the sample period that in turn made all financial ratios such as EPS, DPS, DPR, and PE ratio 
stay in positive territory. Since most of the companies were having consistent profit, the distributed dividends to 
stockholders followed a regular pattern whereas in the emerged market, apart from few big companies, most of 
the companies registered negative net income that affected their EPS which turned out into no dividend to 
shareholders. Though the pharmaceutical sector was generally considered as a non-cyclical industry, the 
fluctuation in GDP, inflation, interest rate, corporate tax, and exchange rate didn't affect the stock price of Indian 
pharmaceutical sector any significantly. But, in the case of the emerged market, fluctuation in corporate tax and 
exchange rate were the main drivers affecting the pharmaceutical industry. 
2. Literature Review 
Literature review section begins by shedding light on key trends and advancements the pharmaceutical 
industry has seen in the last 40 years, with emphasis on its outlook post-2008 global financial crisis. 
Subsequently, it focuses on explicatory research works related to the significance of firm-level factors and 
macroeconomic factors on the price of stocks by analyzing the current and previous studies done by the various 
researches and academicians. This section also gives a chance to understand whether managers and financial 
experts can predict the momentum of stocks more precisely by employing the outcome of these studies. 
Furthermore, by going through the multiple research works and studies, this section also tries to get insight into 
possible relationship between macroeconomic factors and firm-specific factors and impact of their mutual 
influence. 
Pharmaceutical Industry Overview: 
In the last 40 years, the pharmaceutical industry has seen myriads of scientific, technological and legal 
advancements; however, the industry has also been marred by various controversies in areas of clinical trials 
management, approval mechanism, increased pricing and pharmacovigilance.  
 
 
Figure 1: Key Milestones in the pharmaceutical industry (Accenture Research, 2016) 
The key factors driving the Pharmaceutical industry are high R&D cost, the discrepancy between list 
and real price, rising ageing population and high affordability of drugs. As a result, the pharmaceutical industry 
is increasingly moving towards sustainability through more segmentation, robust regulatory framework and 
continuous breakthroughs in New Drug Discovery process. 
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In the wake of the Global economic crisis of 2008, where most of the Industry sectors had been hard hit, 
the pharmaceutical industry remained relatively unscathed. Key underlying factors behind that resilience were 
less sensitivity of economic trends and no price elasticity in time of crisis. 
Despite the relatively modest outlook, biotech and smaller pharmaceutical niche players are feeling the 
pressure because of depleting funding sources on account of the credit crunch. On the other end of the spectrum, 
larger players are also feeling the heat because of intensified scrutiny on healthcare budget by both public and 
private players and that has let to further cost containment measures to reduce drug prices, increase generic 
substitutions and demand for new drug formulation. In contrast with many other industries, pharmaceutical 
companies especially the larger once generally have a strong balance sheet with little debt and therefore have 
maintained stronger leverage in this time of crisis and uncertainty. 
2.1. Theoretical Basis and Development of Hypothesis 
Since financial ratios are the computational result of several inter-connected firm-level factors, it is one 
of the most prevalent ways to make an estimation of the financial and operational efficiency of a firm. The 
financial ratio can be used to determine irregularities in the implementation of the company's operational 
activities by comparing the financial ratio with that of previous years (Wild et al., 2008). Hence, financial ratios 
are being used as a major pointer in order to examine the current position of firm's profitability, liquidity, 
income, utilization of assets, liability, etc., by performing intra-comparative analysis between current report and 
previous report of the same firm or inter-comparative analysis among many firms. 
 
Return on Equity (ROE): Return on equity ratio (ROE) is considered a key measure of a company's 
earnings performance. The ROE provides information to common shareholders on how efficiently their money is 
being used. By analyzing ROE, shareholders can understand whether a firm is profit-enhancing or profit-
depleting and whether management has the profit-earnings ability or not (Kijewska 2016).  A rising ROE can 
signal that a company is able to grow profits without adding new equity into the Business, which dilutes the 
ownership share of existing shareholders (Thorp 2012). 
 
The higher Return on Equity (ROE) implies the higher profitability of firm that shows firm's 
management is utilizing investors' money in an efficient manner and investors can expect a higher rate of return 
on their investments which enhances the overall value of the firm and eventually increases the stock price. This 
ratio is also used to measure the ability of a company to use its own capital to generate profits for all 
shareholders, through both common and preferred stock. An increase in the company's stock price will provide a 
high return for investors. This will further increase the attractiveness of the company for investors. Karnawi 
Kamar (2017), conducted research to see the effect of Return on Equity and Debt to Equity ratio on the share 
price of listed cement companies at the Indonesian stock exchange. Statistical analysis revealed that together 
both factors produce a significant impact on the share price of companies. Moreover, ROE alone demonstrated a 
significant positive relationship with the share price of companies which proves that efficient utilization of 
inventors' money increases the price of shares. On the other hand, Haque and Faruquee (2013), studied the 
impact of fundamental factors on the share price of listed pharmaceutical companies of Dhaka stock exchange 
and found that ROE doesn’t have any effect on the share price of companies. Fouzan Al Qaisi et. Al. (2016), 
showed in their study that ROE didn’t have any effect on the stock price. However, Ursula Tamuntuan (2015), 
found a collective significance of  ROE, ROA, and EPS on the stock price of food and beverages companies at 
Indonesian stock market but, ROE alone didn't produce any significant effect on stock prices. 
Another study conducted by Fitri Sukmawati and Innes Garsela (2016), observed an inverse 
relationship between ROE and Share Price which means an increment in return on equity causes a decrement in 
the share price. Joanna L Saragih (2017), also found that ROE together with ROA and Debt-to-Equity ratio has 
no significant effect on the share price. However, ROE shows the insignificant positive partial effect on the share 
price. 
 
Earnings per Share (EPS): Earning per share (EPS) is generally one of the most important financial 
ratios, uses to evaluate the stock price and the value of the firm. Earnings per share measures the amount of net 
income earned against each share. In other words, this is the amount of money each share of stock would receive 
if all of the profits were distributed to the outstanding shares at the end of the year.  
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EPS are also a calculation that shows how profitable a company is from a shareholder’s perspective. 
Therefore, a larger company's profits per share can be compared to the smaller company's profits per share. 
EPS or basic earnings per share are calculated by subtracting preferred dividends from net income and 
dividing by the weighted average common shares outstanding. 
 
EPS are generally considered to be the single most important variable in determining a share's price. It 
is also a major component used to calculate the price-to-earnings valuation ratio (Besley 2006).  
EPS is a carefully scrutinized metric that is often used as a barometer to gauge a company's profitability 
per unit of shareholder ownership.  As such, earnings per share are a key driver of share prices.  It is also used as 
the denominator in the frequently cited P/E ratio (Md. Rashidul et. al., 2014). 
Pankaj Kumar (2017), studied the influence of EPS on the listed Indian automobile companies. The 
regression result showed a significant effect of EPS on the share price of automobile companies. Budhi 
Suparnihgsih (2017) and Ursula Tamuntuan (2015) found that EPS and other chosen variables simultaneously 
showed a significant effect on the share price of textile and garment companies of Indonesia stock exchange. 
Moreover, a partial significant positive effect of EPS was observed on the stock prices. Subramaniam V. A. and 
Tharshiga Murugesu (2013), studied the effect of the EPS on the share price of listed manufacturing companies 
in Sri Lanka. By employing regression techniques on the sample data, they found a strong significant positive 
relationship between EPS and Share Prices. 
Md. Bellal Hossain and A. H. M. Asaduzzaman (2017) and Sayed Akif and Umara Nareen (2016), also 
supported the significant positive effect on the stock prices of sample companies. Sanjeet Sharma (2011), found 
in his study that EPS showed a significantly positive impact on the share price of sample companies.  
 
Dividend per Share (DPS): Dividends are commonly defined as the distribution of earnings (past or 
present) in real assets among the shareholders of the firm in proportion to their ownership (Kapoor 2009). In 
other words, Dividend per share is the amount of perquisite issued by a firm for every common share 
outstanding. Dividends per share can be calculated by dividing the total number of dividends paid out by a firm, 
including interim dividends, over a period of time, by the number of shares outstanding (investopedia.com). 
 
In a favourable economic environment, raising the dividend amount and frequency gives a very 
prominent signal about the strong performance and higher profitability of the firm to its shareholders. However, 
at times in order to maintain the confidence of shareholders in the firm, many big firms pay dividends on a 
regular basis to their shareholders even after getting an average or weak financial result. 
Onyango Benedict Enrile (2018), conducted a research to understand the relationship between dividend 
per share (DPS) and the stock prices of listed companies at the Nairobi Stock Exchange, where author observed 
that DPS had a positive and significant effect on the share price of companies. Similarly, Sanjeet Sharma (2011), 
also observed a significant positive impact of DPS on share Prices. 
On the other hand, Sayed Akif and Umara Nareen (2016), studied fifty non-financial companies of 
Karachi stock exchange to check the role of dividend policy on stock prices volatility and they found a 
significant negative effect of DPS on stock prices of companies. Similarly, Sebastianus Laurens, (2018) and 
Hashemijoo, M., Ardekani, A. M., &Younesi, N. (2012) also found an inverse relationship between DPS and 
share price of companies. This inverse relationship between DPS and share price supports the dividend 
irrelevance theory. 
 
Dividend Payout Ratio (DPR): According to Akinsulire (2014), the dividend payout ratio is the ratio 
of ordinary dividends to retained earnings. It signifies that what portion of the net profits distributed to 
shareholders as dividends and what portion kept for internal reinvestment. A high payout ratio simply shows a 
liberal distribution of profits whereas a low payout ratio reflects a conservative distribution policy. However, 
from the share valuation model, Simon (2009) asserts that the value of a share depends very much on the amount 
of dividend distributed to shareholders such that the higher the dividend payout ratio, the more attractive the 
share is to the shareholders. 
Conversely, Hasan M, et, al (2015) found in their study that there is a negative impact of dividend 
payout ratio on the profitability of a firm in Pakistan's energy and textile sector. Similarly, Md. Bellal Hossain 
and A. H. M. Asaduzzaman (2017) did a study on the relationship between dividend policy and the stock price of 
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the listed fuel, power, and cement industry of Bangladesh. They applied the random effect panel data regression 
model and observed a negative influence of DPR on stock prices. 
Onyango Benedict Enrile (2018), conducted a research to understand the relationship between dividend 
per share (DPR) and the stock prices listed companies at the Nairobi Stock Exchange, where author observed 
that DPR didn't have any significant effect on the share price of companies whereas another research conducted 
by Hunjra et. al.(2014), to understand role of dividend policy, EPS, ROE, and profit after tax on the stock price. 
The regression result reflected a significant positive correlation between DPR and share price that shows 
distributing more dividends and keeping less retained earnings is a positive signal for increment in share price 
and this result also refutes dividend irrelevance theory.  
 
In practice, decisions as to whether to pay out dividends or not, how much of the profits to pay a 
dividend and in what form the dividend should be paid are influenced by many internal and external factors. 
According to (Alfred, D. D. 2007) there are many internal and external factors such as company's operational 
sector, nature of the company, liquidity constraints, tax constraints, reinvestment opportunity, risk factors, and so 
on can influence the dividend payout strategies of a company. 
 
Price-to-Earnings Ratio (P/E Ratio): The price-earnings ratio (P/E Ratio) is the ratio for assigning a 
value for a firm that measures its current share price relative to its per-share earnings (Nicholson, S. F.1960).The 
price-earnings ratio often called the P/E ratio or price to earnings ratio, is a market prospect ratio that calculates 
the market value of a stock relative to its earnings by comparing the market price per share by the earnings per 
share. 
The price-earnings ratio is normally calculated as the market value per share divided by earnings per 
share. In other words, the price-earnings ratio shows what the market is willing to pay for a stock based on its 
current earnings. 
 
Normally, a high P/E ratio implies that investors are anticipating higher earnings growth within the next 
years while firms with a lower P/E are expected lower growth (Ghaeli, 2017). Investors often use this ratio to 
evaluate what a stock’s fair market value should be by predicting future earnings per share. Companies with 
higher future earnings are usually expected to issue higher dividends or have appreciating stock in the future. 
There are two key drivers responsible for the increment in the P/E ratio; the first one is rapid growth in 
Price-Earnings ratios and the second one is slower growth in dividend yields. Rapid growth in price-earnings 
ratios simply shows the strong confidence of existing investors in a company due to the favourable market-wide 
environment. On the other hand, slower growth in dividend yields shows the company's management strategies 
focusing on reinvestment by employing a bigger chunk of retained earnings. Hence, sometimes lower dividend 
yields give hope to investors to accumulate even better return in future and this situation leads to a higher stock 
price as well as higher P/E ratio. These findings are consistent with Myers's (1984) pecking order and 
stakeholder hypotheses of dividend behaviour. There is also evidence that the P/E ratio is high when the price 
growth rate is high. This study indicates that a high P/E ratio signals faster growth in short-term stock prices 
(Raymond Y. C. Tse., 2002). 
Pankaj Kumar (2017), studied the influence of P/E ratio on the listed Indian automobile companies. The 
regression result showed a significant effect of P/E on the share price of automobile companies.  
Sanjeet Sharma (2011), conducted research on 115 listed companies of six different industries of India. 
Regression analysis showed that the P/E ratio exerts a significant positive impact on the share price of the 
companies. Similarly, Taimur Sharif et. al., (2015), studied the effect of PE ratio along with other firm-specific 
variable and they found that PE ratio is one of the main driving factors for the upward price movement of stocks. 
On the other hand, Onyango Benedict Enrile (2018) and Budhi Suparnihgsih (2017), respectively found positive 
yet insignificant effect and no significant effect of P/E ratio on the stock price. Similarly, AtyHerawati and 
Angger (2018) and George Gatheru Githinji (2011), observed no effect of the P/E ratio on the stock price. 
 
The Asset-Growth Effect: There is a significant and negative relationship between asset growth and 
future stock returns in emerging markets. Watanabe et al. (2012) find a weaker asset-growth effect in emerging 
markets relative to developed markets. In the context of this study, the asset growth effect has been analyzed and 
investigated, with a focus on the global financial crisis of 2008 and compare the existence of the asset-growth 
effect between normal and crisis periods. Since the financial crisis has effects globally on emerged as well as 
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emerging countries, our analysis on stocks traded in emerging markets provides the opportunity to identify 
whether mispricing or optimal investment explanation would find support in those countries. It has been 
observed that the asset-growth effect is stronger during the crisis period relative to more normal periods. During 
the peak year of the Global Financial Crisis, 2008, strong indicators have been found to support the existence of 
the asset growth effect during the crisis period, but not in other periods. 
That points to a significant association between the asset-growth effect and the global financial crisis 
period. The logic is that an episode of crisis gives investors the possibility to improve their assessment of the real 
value of firms’ investment even in those countries where the agency problems and asymmetric information are 
commonly assumed to be higher. 
In particular, the negative relation between asset growth and subsequent taxes returns holds only for the 
subset of firms with low innovation potential. Innovation based firms with high asset growth not only do not 
suffer negative excess returns subsequent to asset growth but actually, earn significantly positive subsequent 
excess returns. In addition, the significantly positive interaction effect between asset growth and innovative 
capacity on subsequent stock returns is robust to the industry effect, the size and BTM effects, and the IE effect 
documented in Hirshleifer et al. (2012). Asset Growth in innovative Pharmaceutical companies driven by huge 
investments and aggressive M&A strategy can generate new growth options. 
 
Gross Domestic Product (GDP): Gross Domestic Product (GDP) is the prime reflector of a country's 
economic growth; it gives a clear view about the degree of growth in almost every type of industry of a country. 
The high tide of economic growth marks the high probability of higher cash flow and low probability of the 
firm's chances to bankrupt, which provides a good environment for higher profitability, investment and so on 
which in turn increases value and stock prices of firms. On the other hand, during the time of economic 
downturn, the situation turns upside down.  
Economic growth occurs when an economy's productive capacity increases, which in turn is used to 
produce more goods and services. Economic growth is measured by an increase in the amount of goods and 
services that are produced in a country. Therefore, a growing economy produces more goods and services each 
successive time period. (Jhingan, M. 1997 Cited in Kampamba Shula (2017)).However, it is not always true that 
we get a correlation between GDP and stock return (www.wise-owl.com).   
 
Inflation Rate: Inflation is always and everywhere a monetary phenomenon in the sense that it is and 
can be produced only by a more rapid increase in the quantity of money than in output. Empirically, the 
variability of inflation tends to increase with the level of inflation, reinforcing the negative effect of higher 
inflation on the quantity of money demanded (Friedman., M. 1987). Higher inflation generally decreases the 
purchasing power of individuals and companies that eventually produces a negative influence on productivity, 
profitability and stock price of firms. Firms operate in a high inflation environment have a lower degree of 
willingness to opt debt financing which disrupts long investment plans and short-term purchasing power of firms 
(Öztekin., Ö. (2015).  
 
Interest Rate: Interest rates greatly affect a company's plan in fulfilling its capital needs, either by 
issuing equity securities or bonds. The low-interest rate will encourage investment and economic activity which 
generates a higher stock price as the result. (Thobarry, A. A. 2009 Cited in Kampamba Shula (2017). Similarly, 
Md. Gazi Salah Uddi and Md. Mahmudul Alam (2010) found an inverse relationship between the interest rate 
and share prices of listed companies at the Dhaka Stock Exchange. Low-interest rates will lead to lower 
borrowing costs since the borrower (the company) is charged to pay less interest. There is a negative relationship 
between the interest rate and borrowing capacity of the firm (Jõeveer, K. (2013). Firm, Country and 
Macroeconomic Determinants of Capital Structure: Evidence from Transition Economics. Journal of 
Comparative Economics, 41(1), 294-308). 
Corporate Tax: Reduction of government economic activity in the past 30 years in the wake of 
sweeping capitalism resulted in limiting both the scope and form of government taxation but the financial crisis 
of 2008 changed this paradigm, as it was expected from federal authorities to once again bail out the situation to 
restore calmness to markets. In this context, taxation became the most important tool of government policy 
(Renata Perić, LjubicaKordić, 2014). 
In the aftermath of the financial crisis of 2008, many pointed out that the reason lies in the fact that too 
many firms had loaded up on debt while relying on only a thin layer of equity. The reason is straightforward: 
whereas equity can absorb a business downturn – profits fall, but the firm does not immediately fail – debt is less 
forgiving because creditors do not wait around to be paid (Mark Roe, 2013, World Economic Forum).  The tax 
system that was skewed towards allowing, firms to use more debt than is safe. Tax deductions for interest 
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payments encourage them to borrow which in turn resulted in more tax-induced lending from financial 
institutions. The tax reform measures, brought in after the global crisis, had both positive and negative impacts 
on the global pharmaceutical investment outlook. Opportunities to access new markets mitigate risk due to 
pricing pressures and patent expirations continued to be the main impetus for the new operating model. 
 Corporate tax rates and repatriation as key drivers spurred M&A activity by making more cash 
available. 
 Many life sciences companies have chosen to keep their intellectual property (IP) rights offshore for tax 
reasons (Jeff Ellis and Dennis Howell, 2018). 
 R&D expenditures to boost new drug discovery and maintain a lucrative pipeline enjoyed cash 
infusions from various tax reforms. Counties like the US are also trying to retain intangible benefits by 
asking companies to amortize the cost of R&D performed onshore and offshore rather than deduct it all 
immediately. 
Exchange Rate: There is no theoretical consensus on the relationship between stock prices and exchange 
rates either. For instance, portfolio balance models of exchange rate determination postulate a negative 
relationship between stock prices and exchange rates and that the causation runs from stock prices to exchange 
rate. In contrast, a positive relationship between stock prices and exchange rates with the direction of causation 
running from exchange rates to stock prices can be explained as follows: domestic currency depreciation makes 
local firms more competitive, leading to an increase in their exports. This, in turn, raises their stock prices. 
A weak or no association between stock prices and exchange rates can also be postulated. The factors/news 
that causes changes in exchange rates may be different from the factors that cause changes in stock prices. Under 
such a scenario, there should be no link between the said variables Muhammad, N and Rasheed, A.,(2002). 
Some studies have found a significant positive relationship between stock prices and exchange rates for 
instance Smith (1992); Solnik (1987)* and Aggarwal (1981)*, while others have reported a significant negative 
relationship between the two e.g., Soenen and Hennigar (1998)*.  On the other hand, there are some studies that 
have found very weak or no association between stock prices and exchange rates, for instance, Franck and 
Young (1972); Bartov and Bodnor (1994)*. Note: *references are cited in Muhammad, N and Rasheed, 
A.,(2002) 
3. Methodology 
3.1. Data Collection: 
The data for this research work has been collected from the different relevant secondary sources such as 
the annual stock price of companies collected from www.Investing.com, other internal data of companies, for 
instance ROE, EPS, DPS, DPR, P/E ratio, and asset from Thomson Router EKion Data Stream, Macroeconomic 
data such as GDP, Inflation Rate, etc from www.knoema.com, and Currency Exchange Rate from 
www.poundsterlinglive.com. Since this research study is related to the pharmaceutical industry of emerging and 
emerged markets, quantitative data of twenty listed companies selected from emerging market (India) and twenty 
listed companies form emerged market (USA, Germany, France, United Kingdom, and Switzerland) have been 
sampled and analyzed.  
Two-panel data have been constructed, first one for the emerging market from the year 2008 to the year 
2017 with 200 observations and the second one for the emerged market for the same period with 181 
observations.  
In this study, selected companies were chosen based on their home countries and stock prices of those 
companies, belonging to their home stock exchanges, were collected along with other firm-specific data, 
retrieved from Thomson Ekion data stream. Since stock prices, EPS, DPS, and Asset of every company were 
collected in their local currency units, the currencies have been converted into US dollars, for the sake of 
congruency. 
The reason behind selecting twenty companies is because most of the mid-sized and small-sized 
companies of the emerged markets are privately held and not listed in stock exchanges. Similarly, due to many 
European Journal of Business and Management                                                                                                                               www.iiste.org 
ISSN 2222-1905 (Paper) ISSN 2222-2839 (Online) 
Vol.11, No.36, 2019 
 
170 
negative and unavailable values of Earnings per share and dividend per share respectively, only 181 observations 
were made for the emerged market companies. 
3.2. Research Methodology 
The multiple regression method has been employed in this study in order to understand the relationship 
between several independent variables and the dependent variable. The independent variables used in this study 
are namely ROE, EPS, DPS, DPR, PER, ASSET, GDPGR, INFR, INTR, CT, and EXCHR whereas the 
dependent variable is MPS. Moreover, panel data model is being used in current course of investigation. There 
are several reasons behind using panel data, such as higher number of informative data, higher level of 
divergence among data, lower chance of collinearity among variables and more degree of freedom, which 
contribute towards constructing a more efficient data model. 
Four steps have been employed: 
 Descriptive statistical analysis to obtain the overview of data in terms of mean, maximum, 
minimum, sum, standard deviation, kurtosis, and so on 
 Correlation test has been employed to check the degree of Multicollinearity. 
 The following are the two types of panel analytic models have been considered: (1) Fixed effect 
model and (2) Random effect model. The fixed effect model is the divergence across cross-
sectional units which can be represented in divergence in the constant term and the intercept term 
of the regression model varies across the cross sectional units whereas the random effect model, the 
individual effects are randomly dispersed across the cross-sectional units and in order to represent 
the individual effects, the regression model is specified with an intercept term which represents an 
overall constant term (Seddighi, 2000) 
 In order to obtain better statistical model between Fixed Effect and Random Effect, the Hausman 
test has been used 
 Fixed effect Panel data regression model has been used to investigate simulations and partial effect 
of independent variables on dependent variables 
 
 
3.3. Research Hypothesis 
This section aims at providing a specific, clear, and testable proposition or predictive statement about 
the possible outcome of this study based on various variables and relationships between them in the context of 
the Pharmaceutical industry. Specifying the research hypotheses is one of the most important steps in planning a 
quantitative research study and it typically states a priori expectation about the research outcome in research 
hypotheses, because the design of the research often is determined by the stated hypotheses. 
 
Figure 2: Conceptual Framework Figure 
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Serial 
Numbe
r 
Variable
s 
Measureme
nt 
Expected  
Hypothes
is 
Key Empirical 
Studies in 
support of 
Expected 
Hypothesis  
Key Empirical 
Studies in 
contrary to 
Expected 
Hypothesis  
Key Empirical 
Studies observed 
no effect of 
Expected 
Hypothesis 
1 Market 
Price of 
Share 
(MPS) 
Annual 
Closing 
Market Price 
of Share  
    
2 Return on 
Equity 
(ROE)  
Net Income / 
Shareholder 
Equity 
+ KarnawiKamar 
(2017),  
FitriSukmawati 
and Innes Garsela 
(2016) 
Haque and 
Faruquee (2013), 
Fouzan Al Qaisi 
et. Al. (2016) 
3 Earnings 
Per Share 
(EPS) 
(Net Income 
– Dividends 
on Preferred 
Stocks) / 
Avg. 
Outstanding 
Shares  
+ BudhiSuparnihgs
ih (2017), Ursula 
Tamuntuan 
(2015), etc 
-------- ------- 
4 Dividend 
Per Share 
(DPS) 
Total 
Dividends – 
Special 
Dividends 
(If Any) / 
Annual 
Weighted 
Average of 
Outstanding 
Shares 
+ Onyango 
Benedict Enrile 
(2018), Sanjeet 
Sharma (2011), 
etc 
SebastianusLaure
ns  (2018), 
Hashemijoo. et.al 
(2012) 
------------ 
5 Dividend 
Payout 
Ratio 
(DPR) 
Dividend Per 
Share / 
Earnings Per 
Share  
_ Hunjra et. al. 
(2014) 
Hasan M  et. al. 
(2015), Hossain 
and A. H. M. 
Asaduzzaman 
(2017) 
Onyango Benedict 
Enrile (2018) 
6 Profit-
Earnings 
Ratio 
(PER) 
Market 
Value Per 
Share 
/Earnings 
Per Share  
+ Pankaj Kumar 
(2017), Sanjeet 
Sharma (2011) 
----------- Aty Herawati and 
Angger (2018), 
George Gatheru 
Githinji (2009) 
7 Asset  
(LASSE
T) 
Company’s 
Total Asset 
+    
8 Gross 
Domestic 
Product  
Growth 
Rate  
(GDPGR
) 
Annual GDP 
Growth Rate 
of 
Countries 
+ Jhingan, M. 
(1997) 
-------- https://www.wise-
owl.com/investme
nt-education/is-
there-a-
correlation-
between-gdp-
growth-and-stock-
market-returns 
9 Inflation 
Rate 
(INFR)  
Annual 
Inflation 
Rate of 
Countries 
- Milton Friedman 
(1987), Öztekin., 
Ö. (2015) 
--------------- -------- 
10 Interest 
Rate  
(INTR)  
 Annual Real 
Interest Rate  
of  
- Md. Gazi 
SalahUddi and 
Md. Mahmudul 
-------------- ---------- 
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Countries Alam (2010), 
Thobarry, A. A. 
(2009) 
11 Corporate 
Tax (CT) 
Annual 
Corporate 
Tax of 
Countries  
- Mark Roe, 2013   
12 Exchange 
Rate  
(EXCHR
) 
Countries’ 
Exchange 
Rate on the 
Last day of 
Financial 
Year of 
Companies  
- Soenen and 
Hennigar (1998) 
Solnik (1987) 
and Aggarwal 
(1981 
Franck and Young 
(1972) 
Table1: Summary Table of Variables, Expected Hypothesis, and Studied Previous results 
 
3.4.    The Model 
MPS it = β0 + β1 ROE it + β2 EPS it + β3 DPS it + β4DPR it + β5 PER it + β6 LASSET it + β7 GDPGR it + β8 INFR 
it + β9 INTR it + β10 CT it + β11 EXCHR it + Ø it 
 MPS it = Market Prices of Share for the Pharmaceutical Companies during the period t 
 ROE it = Effect of Return on Equity (ROE) on MSP of the Pharmaceutical Companies during the 
period t 
 EPS it = Effect of Earnings per Share (EPS) on MSP of the Pharmaceutical Companies during the 
period t 
 DPS it = Effect of Dividend per Share (DPS) on MSP of the Pharmaceutical Companies during the 
period t 
 DPR it = Effect of Dividend Pay Ratio (DPR) on MSP of the Pharmaceutical Companies during the 
period t 
 PER it = Effect of Price Earnings Ratio (PER) on MSP of the Pharmaceutical Companies during the 
period t 
 ASSET it = Effect of Log of Total Assets (LASSET) on MSP of the Pharmaceutical Companies during 
the period t 
 GDPGR it= Effect of GDP (GDPGR) on MSP of the Pharmaceutical Companies during the period t 
 INFR it= Effect of Inflation Rate (INFR) on MSP of the Pharmaceutical Companies during the period t 
 INTR it= Effect of Interest Rate (INTR) on MSP of the Pharmaceutical Companies during the period t 
 CT it= Effect of Corporate Tax (CT) on MSP of the Pharmaceutical Companies during the period t 
 EXCHR it= Effect of Currency Exchange Rate (EXCHR) on MSP of the Pharmaceutical Companies 
during the period t 
 
β0 = Intercept 
β1 – β11 = Coefficient parameters 
Øit = error term 
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4. Findings and Analysis 
4.1. Descriptive Statistics Analysis 
 
MPS ROE EPS DPS DPR PER LASSET GDPGR INFR INTR CT EXCHR
 Mean  5.017152  0.214122  0.263590  0.047207  0.208234  20.55632  5.780051  0.070600  0.077300  0.068960  0.338670  53.86850
 Median  3.019759  0.186500  0.194419  0.034325  0.200525  18.02119  5.610477  0.069000  0.092500  0.073200  0.339900  52.62000
 Maximum  32.14881  0.816000  1.572172  0.301864  1.568615  275.6667  9.155685  0.103000  0.110000  0.080000  0.346100  66.25500
 Minimum  0.135349 -0.070000  0.009611  0.000000  0.000000  0.736363  3.319507  0.039000  0.036000  0.052500  0.324400  39.98000
 Std. Dev.  5.381683  0.118203  0.231940  0.040955  0.160171  22.95119  1.378394  0.016529  0.025755  0.009534  0.007619  8.773534
 Skewness  2.114633  1.416436  2.656942  2.318320  4.871247  7.495629  0.070622  0.061060 -0.407024 -0.467803 -1.027661 -0.031573
 Kurtosis  8.321841  6.664292  13.18731  11.73509  39.16005  79.64759  2.240334  3.005369  1.491282  1.722949  2.725734  1.646541
 Jarque-Bera  385.0724  178.7683  1100.156  815.0016  11687.21  50829.93  4.975352  0.124520  24.49088  20.88515  35.82978  15.29866
 Probability  0.000000  0.000000  0.000000  0.000000  0.000000  0.000000  0.083103  0.939639  0.000005  0.000029  0.000000  0.000476
 Sum  1003.430  42.82440  52.71798  9.441383  41.64673  4111.265  1156.010  14.12000  15.46000  13.79200  67.73400  10773.70
 Sum Sq. Dev.  5763.540  2.780413  10.70540  0.333786  5.105326  104824.6  378.0942  0.054368  0.132002  0.018088  0.011552  15318.00
 Observations  200  200  200  200  200  200  200  200  200  200  200  200  
Table2:  Results Descriptive Statistics Analysis of Indian Pharmaceutical companies (Processed by 
EViews-10) 
 
MPS ROE EPS DPS DPR PER LASSET GDPGR INFR INTR CT EXCHR
 Mean  182.5609  0.103425  2.401576  1.345293  0.868461  172.6613  8.820834  0.012310  0.095880  0.005643  0.307701  0.909303
 Median  42.15102  0.143000  1.922450  1.119050  0.431267  17.55490  9.940290  0.017000  0.015000  0.002500  0.341500  1.000000
 Maximum  3789.540  1.030000  17.26635  8.345960  80.00000  7233.280  12.26881  0.039000  1.650000  0.039500  0.350000  1.064100
 Minimum  1.620000 -4.647000 -5.710000  0.000000 -10.94737 -497.1429  3.081910 -0.056000 -0.011000 -0.007500  0.177700  0.605000
 Std. Dev.  559.6947  0.413980  3.588705  1.612761  6.013378  700.1737  2.530846  0.016686  0.357660  0.007692  0.063275  0.130422
 Skewness  4.698629 -7.659486  1.383203  2.474909  12.65399  6.505117 -0.520661 -1.686224  4.120806  1.835959 -1.242271 -0.964057
 Kurtosis  25.29681  88.33408  6.430707  10.17754  167.6029  57.32034  1.968180  5.564488  18.00747  7.947771  2.812989  2.350414
 Jarque-Bera  4878.801  62638.14  161.8562  576.4683  209165.2  25869.71  17.90837  149.5834  2442.903  316.3618  51.73272  34.49657
 Probability  0.000000  0.000000  0.000000  0.000000  0.000000  0.000000  0.000129  0.000000  0.000000  0.000000  0.000000  0.000000
 Sum  36512.18  20.68508  480.3152  244.8433  157.1914  34359.60  1764.167  2.462000  19.17600  1.128600  61.54020  181.8605
 Sum Sq. Dev.  62338370  34.10449  2562.882  470.7808  6508.929  97068151  1274.631  0.055403  25.45623  0.011775  0.796738  3.384965
 Observations  200  200  200  182  181  199  200  200  200  200  200  200  
Table3: Results Descriptive Statistics Analysis of US & European Pharmaceutical companies (Processed 
by EViews-10) 
 
For Indian pharmaceutical companies, Table 2 shows descriptive statistics analysis of 200 observations 
of for one dependent variable and twelve independent variables. In the case of US and European pharmaceutical 
companies, Table 3 shows descriptive statistics analysis of DPS and DPR with 181 observations, PER with 199 
observations and rest of variables with 200 observations.  
Descriptive statistical analysis of MPS for US and European pharmaceutical companies reflects a key 
difference from Indian pharmaceutical companies by having a huge gap between the minimum (1.620000) and 
maximum (3789.540) MSP value, much higher mean (182.5609), and standard deviation (559.6947). This result 
shows that few companies have had very high share price throughout the taken time period. Similarly, for US 
and European pharmaceutical companies, other variables such as ROE, EPS, DPR, and PER are swinging from 
higher negative value for the minimum to higher positive values for maximum. Moreover, other statistical 
parameters for instance mean and standard deviation are also showing value on the higher side. The reason 
behind this surge could be attributed to a much better performance of few companies over others. 
In the case of Indian pharmaceutical companies, MSP variable has a moderate range from minimum 
(0.135349) to maximum (32.14881) with mean of 5.017152 and standard deviation 5.381683. Similarly, other 
variables such as EPS, DPS, DPR, LASSET, and PER are also showing moderate variation in values for 
minimum, maximum, mean, and standard deviation.  Results show that throughout the observed time period, 
most of the Indian pharmaceutical companies in this study had performed in a reasonable manner. 
Descriptive statistical analysis of Indian as well as US and European pharmaceutical companies also 
depicts that dependent variable (MPS) and many independent variables have skewness greater than 1, which 
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shows high positive skewness whereas few variables have skewness less than -1, which shows high negative 
skewness. Both scenarios explain that data is not symmetrical. However, few variables have positive or negative 
skewness near to 0 which reflects that these variables have better symmetrical distribution than their peers.  
Since all variables have Kurtosis value more than 0, it infers that data distribution of variables has a 
heavier tail, called leptokurtic distribution. Furthermore, Kurtosis results also show that variables are not 
distributed symmetrically. In case of Indian pharmaceutical companies, Jarque-Bera test for checking the 
symmetrical distribution of variables reflects that except LASSET and GDPGR, other variables have probability 
value less than 5%, which shows that variables are not normally distributed. However, in case of US and 
European pharmaceutical companies, Jarque- Bera test for checking the symmetrical distribution of variables 
shows each variable having probability value less than 5%, indicating that variables are not normally distributed. 
 
4.2. Correlation Analysis 
ROE EPS DPS DPR PER LASSET GDPGR INFR INTR CT EXCHR
ROE  1.000000  0.480539  0.263484 -0.136942 -0.161969  0.221006 -0.055083  0.104760  0.052074 -0.074084 -0.156407
EPS  0.480539  1.000000  0.723002 -0.207805 -0.075762  0.128634 -0.024787 -0.269697  0.061018  0.091441  0.249788
DPS  0.263484  0.723002  1.000000  0.124588 -0.053951 -0.013739  0.034329 -0.222783  0.061242  0.098134  0.229039
DPR -0.136942 -0.207805  0.124588  1.000000  0.591633 -0.272037 -0.000456  0.097938  0.088633 -0.084579 -0.021667
PER -0.161969 -0.075762 -0.053951  0.591633  1.000000  0.093046  0.077463 -0.320882  0.059757  0.175649  0.312853
LASSET  0.221006  0.128634 -0.013739 -0.272037  0.093046  1.000000 -0.000143 -0.168783  0.038952  0.060398  0.167452
GDPGR -0.055083 -0.024787  0.034329 -0.000456  0.077463 -0.000143  1.000000 -0.044101 -0.584998  0.289197  0.185959
INFR  0.104760 -0.269697 -0.222783  0.097938 -0.320882 -0.168783 -0.044101  1.000000 -0.009365 -0.643132 -0.842999
INTR  0.052074  0.061018  0.061242  0.088633  0.059757  0.038952 -0.584998 -0.009365  1.000000 -0.457664 -0.049103
CT -0.074084  0.091441  0.098134 -0.084579  0.175649  0.060398  0.289197 -0.643132 -0.457664  1.000000  0.582928
EXCHR -0.156407  0.249788  0.229039 -0.021667  0.312853  0.167452  0.185959 -0.842999 -0.049103  0.582928  1.000000  
Table4: Results Correlation Analysis of Indian Pharmaceutical companies (Processed by EViews-10) 
 
ROE EPS DPS DPR PER LASSET GDPGR INFR INTR CT EXCHR
ROE  1.000000  0.420612  0.329006 -0.003524  0.036733  0.374162  0.100853 -0.019127 -0.147015 -0.226923 -0.025139
EPS  0.420612  1.000000  0.655097 -0.040519 -0.120871  0.447783  0.078046 -0.074960 -0.277622 -0.391630  0.200210
DPS  0.329006  0.655097  1.000000 -0.008333 -0.067289  0.556479  0.073373 -0.055722 -0.261344 -0.494865  0.180711
DPR -0.003524 -0.040519 -0.008333  1.000000  0.265700 -0.003076  0.055695 -0.009277  0.049829  0.017572 -0.072630
PER  0.036733 -0.120871 -0.067289  0.265700  1.000000 -0.031576  0.090410 -0.034270  0.026866 -0.292712 -0.427684
LASSET  0.374162  0.447783  0.556479 -0.003076 -0.031576  1.000000  0.145368  0.072950 -0.180310 -0.110412  0.332583
GDPGR  0.100853  0.078046  0.073373  0.055695  0.090410  0.145368  1.000000  0.175232 -0.271363 -0.080916  0.153838
INFR -0.019127 -0.074960 -0.055722 -0.009277 -0.034270  0.072950  0.175232  1.000000 -0.054430  0.158937  0.143092
INTR -0.147015 -0.277622 -0.261344  0.049829  0.026866 -0.180310 -0.271363 -0.054430  1.000000  0.263986 -0.327848
CT -0.226923 -0.391630 -0.494865  0.017572 -0.292712 -0.110412 -0.080916  0.158937  0.263986  1.000000  0.165459
EXCHR -0.025139  0.200210  0.180711 -0.072630 -0.427684  0.332583  0.153838  0.143092 -0.327848  0.165459  1.000000  
Table5: Results Correlation Analysis of US & European Pharmaceutical companies (Processed by 
EViews-10) 
 
Based on table 4 and 5, the value of correlation coefficient among independent variables of Indian as 
well as US and European pharmaceutical companies can be seen. In the correlation matrix, a correlation 
coefficient shows the extent to which one variable is correlated with others. A positive correlation means any 
increment in one variable causes an increment in other variable and a decrement in one variable causes a 
decrement in other variable similarly in case of negative correlation it is vice versa i.e. an increment in one 
variable causes a decrement in other variables. 
In table 4, the correlation matrix of Indian pharmaceutical companies depicts the higher correlation 
between few variables for instance EPS has highest positive correlation value (0.723002) with DPS followed by 
a positive correlation value (0.591633) between DPR and PER. However, the highest negative correlation value 
(-0.842999) observed between INFR and EXCHR. 
The Correlation matrix of US and European pharmaceutical companies in Table 5, EPS has the highest 
positive correlation with DPS with a correlation value of (0.655097).  The second highest correlation in this 
matrix is the positive correlation value (0.556479) between DPS with LASSET. 
Multicollinearity does not affect the properties of the OLS estimators. The estimator remains unbiased 
and efficient. But the fact is that when multicollinearity is present in the data then the OLS estimators are 
imprecisely estimated (Paul). Since seriousness of multicollinearilty in dataset can be measured through the 
European Journal of Business and Management                                                                                                                               www.iiste.org 
ISSN 2222-1905 (Paper) ISSN 2222-2839 (Online) 
Vol.11, No.36, 2019 
 
175 
degree of correlation among variables, generally, highest degree of accepted correlation between two variables 
should be less than 0.80 (Edhi, A., 2017). By analyzing the correlation matrices of both markets, it can be 
inferred that of the degree of correlation among most variables is less than 0.80. However, negative correlation 
value (-0.842999) is observed between INFR and EXCHR for Indian pharmaceutical market in Table 4 whereas 
and positive correlation value (0.143092) is observed between INFR and EXCHR for European pharmaceutical 
market. Since this study is primarily focusing on comparative analysis between two markets while keeping type 
and number of variables intact in both sides, this higher correlation between INFR and EXCHR for Indian 
pharmaceutical market in Table 4 has been overlooked.   
 
4.3. Regression Analysis 
F-TEST 
The F test is carried out to verify whether the independent variables ROE, EPS, DPS, DPR, PER, 
LASSET, GDPGR, INFR, INTR, CT, and EXCHR combined, can significantly influence the dependent variable 
MSP of companies. 
Hypothesis: There is a simultaneous significant influence of independent variables on the dependent 
variable.  
Indian Pharmaceutical companies US and European Pharmaceutical companies 
Result of the F test (simultaneous coefficient test) 
shows that F-statistic of 32.32335 with significance 
below (0.000000<0.05). It can be concluded that 
together with ROE, EPS, DPS, DPR, PER, LASSET, 
GDPGR, INFR, INTR, CT, and EXCHR have a 
simultaneous significant effect on MSP of Indian 
Pharmaceutical Companies.  
Hypothesis Accepted 
Result of the F test (simultaneous coefficient test) 
shows that F-statistic of 99.05622 with significance 
below (0.000000<0.05). It can be concluded that 
together with ROE, EPS, DPS, DPR, PER, LASSET, 
GDPGR, INFR, INTR, CT, and EXCHR have a 
simultaneous significant effect on MSP of US and 
European Pharmaceutical Companies.  
Hypothesis Accepted 
Regression Result Summary 
Dependent Variable: MPS
Method: Panel Least Squares
Date: 04/22/19   Time: 21:17
Sample: 2008 2017
Periods included: 10
Cross-sections included: 20
Total panel (balanced) observations: 200
Variable Coefficient Std. Error t-Statistic Prob.  
C -16.60750 16.20192 -1.025032 0.3068
ROE -8.035798 3.537531 -2.271584 0.0244
EPS 7.059722 2.073999 3.403919 0.0008
DPS 61.00841 9.119055 6.690212 0.0000
DPR -7.331832 2.236580 -3.278144 0.0013
PER 0.061568 0.013690 4.497197 0.0000
LASSET 2.031314 0.975845 2.081595 0.0389
GDPGR -1.596778 12.73396 -0.125395 0.9004
INFR -27.03355 15.69895 -1.721998 0.0869
INTR -15.50890 25.39091 -0.610805 0.5421
CT 37.90745 36.99307 1.024718 0.3070
EXCHR -0.045328 0.038517 -1.176839 0.2409
Effects Specification
Cross-section fixed (dummy variables)
R-squared 0.851585     Mean dependent var 5.017152
Adjusted R-squared 0.825239     S.D. dependent var 5.381683
S.E. of regression 2.249779     Akaike info criterion 4.601123
Sum squared resid 855.3947     Schwarz criterion 5.112362
Log likelihood -429.1123     Hannan-Quinn criter. 4.808013
F-statistic 32.32335     Durbin-Watson stat 1.564283
Prob(F-statistic) 0.000000
 
Figure 4: Regression Result of Panel Data of Indian Pharmaceutical companies (Processed by EViews-10) 
Regression result of panel data of Indian pharmaceutical companies summarizes the regression test 
model in the following sections. 
The regression output summary of Indian pharmaceutical companies revealed an R-squared value of 
0.851585 which means that 85.1585% of the variation in the market share price of Indian pharmaceutical 
companies can be explicated by the independent variables included in the current study. Result of the F-test 
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(simultaneous coefficient test) also shows that F-statistic value of 32.32335 with significance below 
(0.000000<0.05) validates the inclusive simultaneous effect of all independent variables on the market price of a 
share of Indian pharmaceutical companies. 
ROE for Indian Pharmaceutical companies has the negative coefficient value of -8.035798 and 
probability (0.0244<0.05), which implies that the ROE has a significant negative effect on the MSP that is why 
H0 can be deemed rejected. This result supports previous studies of Fitri Sukmawati and Innes Garsela (2016). 
Independent variable EPS with positive coefficient value of 7.059722 and probability value of 
(0.0008<0.05) reflects that EPS has a significant positive effect on MSP of Indian pharmaceutical companies 
and thus H1can be deemed validated, which falls in line with the previous studies of Budhi Suparnihgsih (2017), 
Ursula Tamuntuan (2015).  
Similarly, the regression output of DPS for Indian pharmaceutical companies gives a positive 
coefficient value of 61.00841 with a probability value of (0.0000<0.05). Therefore, DPS can be considered to 
have a significant positive effect on the market share price which ratifies H2and supports previous studies of 
Onyango Benedict Enrile (2018), Sanjeet Sharma (2011), etc.  
However, Regression output of DPR has the negative coefficient value of -7.331832 and probability 
value of (0.0013<0.05) which depicts DPR with the significant negative effect on the stock price that means H3 
is accepted and supports previous studies of Hunjra et. al.(2014). Regression output indicates that the estimation 
result of PER for Indian pharmaceutical companies shows a positive coefficient value of 0.061568 with a 
probability value of (0.0000<0.05). It reflects that the PER has a significant positive effect on the market share 
price, which is in line with H4and supports previous studies of Pankaj Kumar (2017), Sanjeet Sharma (2011). 
Similarly, Regression output result of LASSET with positive coefficient value of 2.031314 and 
probability value lower than the specified significance level of 5% (0.0389<0.05), reflects that the LASSET has 
a significant positive effect on the stock price of Indian Pharmaceutical companies, hence it can be concluded 
that H5 is accepted.  
Regression result of macroeconomic variables such as GDPGR, INFR, INTR, CT, and EXCHR doesn’t 
show any significant effect on the market share price of Indian pharmaceutical companies. Hence, hypothesisH6, 
H7, H8, H9, and H10 are rejected.  
Dependent Variable: MPS
Method: Panel Least Squares
Date: 04/22/19   Time: 21:56
Sample: 2008 2017
Periods included: 10
Cross-sections included: 20
Total panel (unbalanced) observations: 181
Variable Coefficient Std. Error t-Statistic Prob.  
C 1759.451 454.4975 3.871201 0.0002
ROE 24.38475 36.24807 0.672718 0.5022
EPS 3.928813 6.061408 0.648168 0.5179
DPS 33.59069 31.44775 1.068143 0.2872
DPR -3.617106 2.025520 -1.785767 0.0762
PER 0.112454 0.026697 4.212300 0.0000
LASSET -21.14702 27.00078 -0.783201 0.4347
GDPGR -51.14591 688.0880 -0.074330 0.9408
INFR 14.50280 35.55964 0.407844 0.6840
INTR 2468.204 1683.991 1.465687 0.1448
CT -7053.961 1062.856 -6.636798 0.0000
EXCHR 743.9563 221.1875 3.363465 0.0010
Effects Specification
Cross-section fixed (dummy variables)
R-squared 0.951949     Mean dependent var 192.5727
Adjusted R-squared 0.942339     S.D. dependent var 586.6521
S.E. of regression 140.8712     Akaike info criterion 12.88825
Sum squared resid 2976705.     Schwarz criterion 13.43606
Log likelihood -1135.387     Hannan-Quinn criter. 13.11034
F-statistic 99.05622     Durbin-Watson stat 0.412744
Prob(F-statistic) 0.000000
 
Figure 5: Regression Result of Panel Data of US and European Pharmaceutical companies (Processed by 
EViews-10) 
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Regression result of panel data of US and European pharmaceutical companies summarizes the 
regression test model in the following sections. 
The regression output summary of US and European pharmaceutical companies revealed an R-squared 
value of 0.951949 which means that 95.1949 % of the variation in the market share price of US and European 
pharmaceutical companies can be explicated by the independent variables included in the current study. Result 
of the F-test (simultaneous coefficient test) also shows that F-statistic value of 99.05622 with significance below 
(0.000000<0.05) supporting the inclusive simultaneous effect of all independent variables on the market price of 
a share of US and European pharmaceutical companies. 
In the case of US and European pharmaceutical companies, most of the microeconomic variables such 
as ROE, EPS, DPS, DPR, and LASSAT don't have any significant effect on the market share price of US and 
European pharmaceutical companies. Hence, hypothesis H0, H1, H2, H3, and H5 are rejected. However, 
microeconomic variable namely PER shows a positive and significant effect on the market share price of US and 
European pharmaceutical companies with a coefficient value of 0.076573 and probability value (0.0000<0.05) 
respectively. Therefore, Hence, H4 is accepted and the result supports previous studies of Pankaj Kumar (2017), 
Sanjeet Sharma (2011). 
Regression result of macroeconomic variables such as GDPGR, INFR, and INTR don't show any 
significant effect on the market share price of US and European pharmaceutical companies. Hence, hypothesis 
H6, H7, and H8, are rejected. However, macroeconomic variables such as CT and EXCHR for US and European 
companies show the negative coefficient value of -7053.961 and positive coefficient 743.9563 respectively, 
while having probability value of (0.0000>0.05) for both variables. This result shows that CT and EXCHR have 
significant negative effect and positive effect respectively on the market share price of US and European 
pharmaceutical companies. Hence, hypothesis H9 is accepted which supports the previous study of Mark Roe 
(2013), whereas hypothesis H10 is rejected and supports the precious study of Solnik (1987) and Aggarwal 
(1981) and refutes the previous study done by Soenen and Hennigar (1998). 
 Indian Pharmaceutical companies US and European Pharmaceutical companies 
S.
N 
Name of  
Variable
s 
Coefficien
t 
 value 
Significance 
 level 
Result Name of  
Variable
s 
Coefficient  
value 
Significance 
 level 
Result 
(a) ROE -8.035798 (0.0244 
<0.05) 
Significan
t negative 
effect. H0 
Rejected 
ROE 24.38475 (0.5022>0.0
5) 
Insignificant 
effect. H0 
rejected 
(b) EPS 7.059722 (0.0008<0.05
) 
Significan
t positive 
effect. H1 
accepted 
EPS 3.928813 (0.5179>0.0
5) 
Insignificant 
effect. H1 
rejected 
(c) DPS 61.00841 (0.0000<0.05
) 
Significan
t positive 
effect. H2 
accepted 
DPS 33.59069 (0.2872>0.0
5) 
Insignificant 
effect. H2 
 rejected 
(d) DPR -7.331832 (0.0013<0.05
) 
Significan
t negative 
effect. H3 
accepted 
DPR -3.617106 (0.0762>0.0
5) 
Insignificant 
effect. H3 
 rejected 
(e) PER 0.061568 (0.0000<0.05
) 
Significan
t positive 
effect. H4 
accepted 
PER 0.112454 (0.0000<0.0
5) 
Significant 
positive 
partial 
effect. H4 
accepted 
(f) LASSET 2.031314 (0.0389<0.05
) 
Significan
t positive 
effect. H5 
accepted 
LASSET -21.14702 (0.4347>0.0
5) 
Insignificant 
effect. H5 
rejected 
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(g) GDPGR -1.596778 
 
(0.9004>0.05
) 
Insignific
ant effect. 
H6 
rejected 
GDPGR -51.14591 (0.9408>0.0
5) 
Insignificant 
effect. H6 
 rejected  
(h) INFR -27.03355 
 
(0.0869>0.05
) 
Insignific
ant effect. 
H7 
rejected 
INFR 14.50280 (0.6840>0.0
5) 
Insignificant 
effect. H7 
rejected 
(i) INTR -15.50890 
 
(0.5421>0.05
) 
Insignific
ant effect. 
H8 
rejected 
INTR 2468.204 (0.1448>0.0
5) 
Insignificant 
effect. H8  
rejected 
(j) CT 37.90745 
 
(0.3070>0.05
) 
Insignific
ant effect. 
H9 
rejected 
CT -7053.961 (0.0000<0.0
5) 
Significant 
negative  
effect. H9 
accepted 
(k) EXCHR -0.045328 
 
(0.2409>0.05
) 
Insignific
ant effect. 
H10reject
ed 
EXCHR 743.9563 (0.0010<0.0
5) 
Significant 
positive 
effect. 
H10rejected 
Table 6: Comparative Analysis of Regression Result between Emerging and Emerged Market 
5. Conclusion and Recommendations 
The main objective of this study was to investigate the effect of internal (microeconomic) and external 
(macroeconomic) factors on the market price of a share of pharmaceuticals companies of emerging market 
(India) and emerged market (the US and Europe). During the course of study, 200 observations for emerging 
market and 181 observations for emerged markets, were examined and analyzed to understand the diverse 
behaviour of the same variables in emerging and emerged markets. The statistical estimation method was based 
on panel OLS regression while considering the fixed effect model. This research strived to establish an 
association between the market price of the share (MPS) and other eleven variables for both emerging and 
emerged markets separately. 
The empirical findings show a positive and significant relationship between EPS, DPS, PER, and 
LASSET with market price of the share (MPS) for emerging (India) market. This significant positive relation 
with MPS explains why higher EPS and DPS make companies more attractive for investment. Similarly, PER 
exerts the same impact on companies by making investors willing to buy their share at current market price even 
during the rally and thus fuel the overall upward growth. On the same note, higher LASSET growth boosts 
confidence in investors towards companies’ growth and investment outlook. Having said that, significant 
negative relation of ROE and DPR with MPS show that higher return on equity causes decrement in share price 
because of possible approach of middle size companies in aggressive reinvestment of retained earnings and 
investors’ money towards their expansion. Therefore, higher dividend payout ratio causes apprehension in 
investor’s mind about investment and growth policy of companies and that affects MPS in a negative manner.  
Since pharmaceutical companies are considered the non-cyclical industry, with better immunity against 
macroeconomic fluctuations, this study further reinforces that macroeconomic factors such as GDP growth, 
Inflation rate, interest rate and exchange rate do not affect significantly the market price of a share of 
pharmaceutical companies of the emerging market. In the case of emerged markets, most of the internal factors 
except PER do not show any significant effect on the MPS of US and European pharmaceutical companies. The 
possible reason behind this result could be the weak effect of ROE, EPS, DPS, and DPR on the MSP. As per 
data, these factors for many middle size pharmaceutical companies of the emerged market show that although 
they had negative EPS and they didn’t pay DPS due to negative net income, MPS wasn’t affected severely. 
Moreover, significant positive relationship between PER and MPS also brings to fore a crucial fact that despite 
successive bad results and unattractive dividend policies, investors showed their confidence in those companies. 
In emerged markets, the story is rather different. This study reveals macroeconomic factors such as GDP growth, 
Inflation rate and Interest rate, do not affect significantly the market price of a share of pharmaceutical 
companies of the emerged market. However, higher fluctuation in corporate tax and variation in exchange rates 
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show a significant negative and positive effect respectively on the MPS of pharmaceutical companies of the 
emerged market. The probable reason behind it could be the close relationship between the European and US 
economy. 
Possible recommendations promulgated by this study are stemmed firmly into the domains of micro and 
macroeconomics factors affecting key performance of pharmaceutical companies of emerging and emerged 
markets. During the research, pharmaceutical companies from five countries in the emerged market and one 
country in the emerging market have been considered to study the patterns of stock price changes. Along the 
same line, this methodology can also be implemented to study the pharmaceutical companies of each country 
separately, to achieve a more comprehensive and precise results, which can be helpful for investors and 
managers to understand and predict the stock patterns before investing their capital in pharmaceutical stocks. 
Also, the further studies can be helpful for the investors to comprehend the potentials of different countries in the 
field of pharmaceutical developments beforehand. In conclusion, it is worthwhile to mention that this study has 
paved the path to delve deeper into financial conditions of pharmaceutical companies of different countries from 
a novel perspective.    
 
6. Limitations 
Considering a few limitations of financial ratios, in some situations, financial ratios don't necessarily 
give very precise financial information such as distorted balance sheet of the firm due to inflation, different 
accounting policies in place and practices of different firms (https://www.thebalancesmb.com/limitations-of-
financial-ratio-analysis-393236). 
Since many middle and small-sized pharmaceutical companies in the USA and Europe are private 
entities and not listed in the stock exchange, only twenty companies have been taken from emerged markets in 
this study. 
Huge difference in operational, financial, other parameters between big and small emerged companies 
may cause biased regression results.  
This study gives a generalized idea about the effect of internal and external factors on the stock price of 
pharmaceutical companies in emerging and emerged market and how these factors behave differently in a 
different market. 
This study doesn't give a complete picture of share price fluctuation in the pharmaceutical sector of the 
entire emerging and emerged markets. 
In this study, in order to compare the regression results of pharmaceutical companies, in both emerging 
and emerged markets, fixed effect model has employed. Additionally, Hausman test has been performed and it 
was inferred that Random effect would have been more appropriate for Indian firms but considering the 
objective of this study, which is doing a comparative analysis of regression results of two different markets, the 
fixed effect was given chosen instead of random effect. 
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Appendices: 
 
Key Financial Data of Selected Companies: 
Yea
r  
Firm Specific Data of Indian Pharmaceutical Companies 
Annual Financial data in millions of US Dollars 
 
Sun 
Pharmaceuticals 
India 
Lupin Limited  
India 
Cipla Limited 
India 
Unichem 
Laboratory Ltd. 
India 
Cadila 
Healthcare 
India 
2007
-
2008 
MPS:2.82466233
1 
ROE:38.30% 
EPS:0.186843422 
DPS:0.026263 
DPR:0.141 
PE_RATIO:15.1
18 
ASSET:1520.460
23 
MPS:2.47073536
8 
ROE: 37.90% 
EPS: 
0.250125063 
DPS:0.025013 
DPR:0.100 
PE_RATIO:9.87
8 
ASSET:842.8464
232 
MPS:5.49649824
9 
ROE:20.10%  
EPS: 
0.225612806 
DPS:0.050025 
DPR:0.222 
PE_RATIO:24.3
63 
ASSET:1433.866
933 
MPS:1.30115057
5 
ROE:12.80% 
EPS:0.142571286
  
DPS:0.050025 
DPR:0.351 
PE_RATIO:9.12
6 
ASSET:151.5757
879 
MPS:0.80165082
5 
ROE:26.80% 
EPS:0.068284142 
DPS:0.015008 
DPR:0.220 
PE_RATIO:11.7
40 
ASSET:637.2686
343 
2008
-
2009 
MPS:2.19600869
4 
ROE:30.20% 
EPS:0.173483501 
MPS:2.72357241
7 
ROE:37.10% 
EPS:0.240466311 
MPS:4.34202726
7 
ROE: 19.00% 
EPS:0.196008694
MPS:1.26812882
8 
ROE: 24.10% 
EPS: 
MPS:0.71685437
7 
ROE:25.70% 
EPS:0.058486465 
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DPS:0.027267 
DPR:0.157 
PE_RATIO:12.6
58 
ASSET:1632.780
083 
DPS:0.049397 
DPR:0.205 
PE_RATIO:11.3
26 
ASSET:793.7759
336 
  
DPS:0.039518 
DPR:0.202 
PE_RATIO:22.1
52 
ASSET:1316.301
126 
0.236909702 
DPS:0.063229 
DPR:0.267 
PE_RATIO:5.35
3 
ASSET:139.7945
07 
DPS:0.011855 
DPR:0.203 
PE_RATIO:12.2
57 
ASSET:668.5437
661 
2009
-
2010 
MPS:3.99776910
2 
ROE:18.20% 
EPS:0.145454545 
DPS:0.030786 
DPR:0.212 
PE_RATIO:27.4
85 
ASSET:2023.892
917 
MPS:7.24841048
5 
ROE:34.10% 
EPS:0.353374233 
DPS:0.060234 
DPR:0.170 
PE_RATIO:20.5
12 
ASSET:1134.523
146 
MPS:7.52035694
4 
ROE: 21.10% 
EPS:0.305633017
  
DPS:0.044618 
DPR:0.146 
PE_RATIO:24.6
06 
ASSET:1630.585
611 
MPS:3.58148354
7 
ROE:23.50% 
EPS: 
0.304740658 
DPS:0.089236 
DPR:0.293 
PE_RATIO:11.7
53 
ASSET:179.1634
133 
MPS:2.45398773 
ROE:35.30% 
EPS:0.111098717 
DPS:0.014947 
DPR:0.135 
PE_RATIO:22.0
88 
ASSET:844.2833
24 
2010
-
2011 
MPS:4.96911847
3 
ROE:21.00% 
EPS:0.196967996 
DPS:0.039304 
DPR:0.200 
PE_RATIO:25.2
28 
ASSET:2778.910
724 
MPS:9.32846715
3 
ROE:29.50%  
EPS:0.434811903 
DPS:0.067378 
DPR:0.155 
PE_RATIO:21.4
54 
ASSET:1375.496
912 
MPS:7.21055586
7 
ROE:15.70%  
EPS:0.276698484
  
DPS:0.062886 
DPR:0.227 
PE_RATIO:26.0
59 
ASSET:1930.758
001 
MPS:4.25154407
6 
ROE:16.10% 
EPS:0.23649635  
DPS:0.089837 
DPR:0.380 
PE_RATIO:17.9
77 
ASSET:197.9337
451 
MPS:3.55440763
6 
ROE:37.40% 
EPS:0.156092083 
DPS:0.028074 
DPR:0.180 
PE_RATIO:22.7
71 
ASSET:1035.508
141 
2011
-
2012 
MPS:5.59277794
1 
ROE:24.50% 
EPS:0.251790796 
DPS:0.041802 
DPR:0.166 
PE_RATIO:22.2
12 
ASSET:3233.048
769 
MPS:10.3944657
1 
ROE:23.80% 
EPS:0.381316848 
DPS:0.062801 
DPR:0.165 
PE_RATIO:27.2
59 
ASSET:1566.519
478 
MPS:5.97684231
2 
ROE:16.00%  
EPS:0.279658522
  
DPS:0.03925 
DPR:0.140 
PE_RATIO:21.3
72 
ASSET:1834.913
159 
MPS:2.59248356
4 
ROE:11.10% 
EPS:0.154842508
  
DPS:0.058875 
DPR:0.380 
PE_RATIO:16.7
43 
ASSET:193.6218
232 
MPS:2.98341674 
ROE:27.40% 
EPS:0.125012266 
DPS:0.029438 
DPR:0.235 
PE_RATIO:23.8
65 
ASSET:1260.523
992 
2012
-
2013 
MPS:7.54315188
4 
ROE:22.00% 
EPS:0.265266648 
DPS:0.046053 
DPR:0.174 
PE_RATIO:28.4
36 
ASSET:3791.599
889 
MPS:11.5879156
3 
ROE:28.50% 
EPS:0.541401861 
DPS:0.073685 
DPR:0.136 
PE_RATIO:21.4
04 
ASSET:1642.055
817 
MPS:6.99548678
3 
ROE:18.50%   
EPS: 
0.354425716 
DPS:0.036843 
DPR:0.104 
PE_RATIO:19.7
38 
ASSET:2147.701
943 
MPS:3.18412084
4 
ROE:16.30% 
EPS: 
0.230634614 
DPS:0.082896 
DPR:0.359 
PE_RATIO:13.8
06 
ASSET:197.5683
891 
MPS:2.73132541
2 
ROE:23.60% 
EPS:0.117527862 
DPS:0.027632 
DPR:0.235 
PE_RATIO:23.2
40 
ASSET:1358.423
137 
2013
-
MPS:9.58555703
8 
ROE:18.80% 
MPS:15.6087391
6 
ROE:30.30% 
MPS:6.39926617
7 
ROE:14.60%  
MPS:3.82338225
5 
ROE:16.60% 
MPS:3.42361574
4 
ROE:25.20% 
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2014 EPS:0.253002001 
DPS:0.025017 
DPR:0.099 
PE_RATIO:37.8
87 
ASSET:4898.398
933 
EPS:0.683622415 
DPS:0.100067 
DPR:0.146 
PE_RATIO:22.8
32 
ASSET:1702.134
75 
EPS:0.288358906
  
DPS:0.033356 
DPR:0.116 
PE_RATIO:22.1
92 
ASSET:2235.356
905 
EPS:0.311707805
  
DPS:0.133422 
DPR:0.428 
PE_RATIO:12.2
66 
ASSET:190.9106
071 
EPS:0.130920614 
DPS:0.03002
 0.229 
DPR:0.229 
PE_RATIO:26.1
50 
ASSET:1331.971
314 
2014
-
2015 
MPS:16.4007688
6 
ROE:19.50% 
EPS:0.302418709 
DPS:0.048054 
DPR:0.159 
PE_RATIO:54.2
32 
ASSET:8034.614
769 
MPS:32.1488066
6 
ROE:29.80% 
EPS:0.856158898 
DPS:0.120135 
DPR:0.140 
PE_RATIO:37.5
50 
ASSET:2124.139
03 
MPS:11.3919589
9 
ROE:11.40%  
EPS: 
0.235623899 
DPS:0.032036 
DPR:0.136 
PE_RATIO:48.3
48 
ASSET:2506.343
104 
MPS:3.26125260
3 
ROE:8.80% 
EPS: 
0.133109082 
DPS:0.032036 
DPR:0.241 
PE_RATIO:24.5
01 
ASSET:187.1856
479 
MPS:5.57200064
1 
ROE:28.90% 
EPS:0.180041647 
DPS:0.038443 
DPR:0.214 
PE_RATIO:30.9
48 
ASSET:1463.110
684 
2015
-
2016 
MPS:4.22609614
4 
ROE:14.90% 
EPS:0.29582673 
DPS:0.015093 
DPR:0.051 
PE_RATIO:14.2
86 
ASSET:8381.299
525 
MPS:21.8889140
4 
ROE:22.20% 
EPS:0.761451966 
DPS:0.113199 
DPR:0.149 
PE_RATIO:28.7
46 
ASSET:3414.821
523 
MPS:7.73073730
3 
ROE:12.30%  
EPS:0.255527885
  
DPS:0.030186 
DPR:0.118 
PE_RATIO:30.2
54 
ASSET:3188.921
591 
MPS:3.34993585
4 
ROE:11.70% 
EPS: 
0.179609086 
DPS:0.030186 
DPR:0.168 
PE_RATIO:18.6
51 
ASSET:193.7514
15 
MPS:4.78378990
3 
ROE:37.80%  
EPS:0.224435892 
DPS:0.048298 
DPR:0.215 
PE_RATIO:21.3
15 
ASSET:1592.423
213 
2016
-
2017 
MPS:10.6097749 
ROE:20.00% 
EPS:0.446808511 
DPS:0.053962 
DPR:0.121 
PE_RATIO:23.7
46 
ASSET:9468.115
942 
MPS:22.2756706
8 
ROE:20.70% 
EPS:0.874036386 
DPS:0.115634 
DPR:0.132 
PE_RATIO:25.4
86 
ASSET:4102.266
42 
MPS:9.13197656
5 
ROE:8.40%  
EPS:0.193031144
  
DPS:0.030836 
DPR:0.160 
PE_RATIO:47.3
08 
ASSET:3243.462
843 
MPS:4.41335183
5 
ROE:-7.00% 
EPS:0.184397163
  
DPS:0.046253 
DPR:0.251 
PE_RATIO:23.9
34 
ASSET:235.3684
86 
MPS:6.83395004
6 
ROE:23.50% 
EPS:0.224020968 
DPS:0.049337 
DPR:0.220 
PE_RATIO:30.5
06 
ASSET:2346.700
586 
 
Yea
r  
Firm Specific Data of Indian Pharmaceutical Companies 
Annual Financial data in millions of US Dollars 
 
Glenmark 
Pharmaceuticals 
 Ltd India 
TTK Healthcare 
India 
IPCA  Laborator
ies India  
Torrent  
Pharmaceuticals 
India  
Biocon Ltd. 
India 
2007
-
2008 
MPS:12.2736368
2 
ROE57.40%: 
EPS:0.646323162 
DPS:0.017509 
DPR:0.027 
PE_RATIO:18.9
MPS:1.77588794
4 
ROE:23.10% 
EPS:0.375937969 
DPS:0.075038 
DPR:0.200 
PE_RATIO:4.72
MPS:3.04502251
1 
ROE:25.50% 
EPS:0.271635818 
DPS:0.04002 
DPR:0.147 
PE_RATIO:11.2
MPS:1.76838419
2 
ROE:29.30% 
EPS:0.19909955 
DPS:0.043772 
DPR:0.220 
PE_RATIO:8.88
MPS:1.79514757
4 
ROE:37.20% 
EPS:0.20010005 
DPS:0.012506 
DPR:0.062 
PE_RATIO:8.97
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90 
ASSET:736.7683
842 
4 
ASSET:30.46773
387 
10 
ASSET:290.6203
102 
2 
ASSET:318.6843
422 
1 
ASSET:519.9849
925 
2008
-
2009 
MPS:3.11796087
7 
ROE:12.30% 
EPS:0.151551077 
DPS:0.007904 
DPR:0.052 
PE_RATIO:20.5
74 
ASSET:841.2369
097 
MPS:1.88203912
3 
ROE:13.18% 
EPS:0.191859316 
DPS:0.059277 
DPR:0.309 
PE_RATIO:9.80
9 
ASSET:27.64671
014 
MPS:1.29994072
3 
ROE:16.50% 
EPS:0.158664296 
DPS:0.04347 
DPR:0.274 
PE_RATIO:8.19
3 
ASSET:271.6064
019 
MPS:1.32444181 
ROE:31.80% 
EPS:0.215372456 
DPS:0.039518 
DPR:0.183 
PE_RATIO:6.15
0 
ASSET:329.4803
399 
MPS: 
0.951788184 
ROE:6.21% 
EPS:0.031811895 
DPS:0.019759 
DPR:0.621 
PE_RATIO:29.9
19 
ASSET:502.5884
213 
2009
-
2010 
MPS:5.93976575
6 
ROE:16.40% 
EPS:0.277523703 
DPS:0.008924 
DPR:0.032 
PE_RATIO:21.4
03 
ASSET:1089.525
934 
MPS:5.71890686 
ROE:14.40% 
EPS:0.260568879 
DPS:0.078081 
DPR:0.300 
PE_RATIO:21.9
48 
ASSET:34.60122
699 
MPS:6.01896263
2 
ROE:27.50% 
EPS:0.366759621 
DPS:0.062465 
DPR:0.170 
PE_RATIO:16.4
11 
ASSET:360.7808
143 
MPS:6.08075850
5 
ROE:31.20% 
EPS:0.304740658 
DPS:0.066927 
DPR:0.220 
PE_RATIO:19.9
54 
ASSET:438.4160
625 
MPS:2.11444506
4 
ROE:17.90% 
EPS:0.112214166 
DPS:0.026102 
DPR:0.233 
PE_RATIO:18.8
43 
ASSET:655.0139
431 
2010
-
2011 
MPS:6.36945536
2 
ROE:20.60% 
EPS:0.376866929 
DPS:0.008984 
DPR:0.024 
PE_RATIO:16.9
01 
ASSET:1144.929
815 
MPS:9.07018528
9 
ROE:20.96% 
EPS:0.425828186 
DPS:0.089837 
DPR:0.211 
PE_RATIO:21.3
00 
ASSET:43.32172
937 
MPS:6.77372262
8 
ROE:27.40% 
EPS:0.470746771 
DPS:0.07187 
DPR:0.153 
PE_RATIO:14.3
89 
ASSET:429.3767
546 
MPS:6.49477821
4 
ROE:29.20% 
EPS:0.358674902 
DPS:0.067378 
DPR:0.188 
PE_RATIO:18.1
08 
ASSET:572.5772
038 
MPS:2.57495788
9 
ROE:19.39% 
EPS:0.140595171 
DPS:0.033689 
DPR:0.240 
PE_RATIO:18.3
15 
ASSET:805.3003
93 
2011
-
2012 
MPS:6.03768030
6 
ROE:10.70% 
EPS:0.334216466 
DPS:0.03925 
DPR:0.117 
PE_RATIO:18.0
65 
ASSET:1154.626
631 
MPS:7.67049357
3 
ROE:19.13% 
EPS:0.39505446 
DPS:0.078501 
DPR:0.199 
PE_RATIO:19.4
16 
ASSET:37.75488
176 
MPS:6.57442841
7 
ROE:24.00% 
EPS:0.431361005 
DPS:0.062801 
DPR:0.146 
PE_RATIO:15.2
41 
ASSET:456.7363
36 
MPS:6.16858012 
ROE:25.60% 
EPS:0.329310176 
DPS:0.083407 
DPR:0.253 
PE_RATIO:18.7
32 
ASSET:600.4710
038 
MPS:1.55725640
3 
ROE:15.70% 
EPS:0.113040918 
DPS:0.032774 
DPR:0.290 
PE_RATIO:13.7
76 
ASSET:774.2125
405 
2012
-
2013 
MPS:8.52077001 
ROE:24.00% 
EPS:0.422031869 
DPS:0.036843 
DPR:0.087 
PE_RATIO:20.1
90 
ASSET:1320.991
066 
MPS:7.44496638
1 
ROE:15.30% 
EPS:0.336925486 
DPS:0.073685 
DPR:0.219 
PE_RATIO:22.0
97 
ASSET:38.56498
112 
MPS:9.70065395
6 
ROE:23.00% 
EPS:0.472506217 
DPS:0.073685 
DPR:0.156 
PE_RATIO:20.5
30 
ASSET:496.8223
266 
MPS:6.40361057
4 
ROE:33.10% 
EPS:0.471032514 
DPS:0.119738 
DPR:0.254 
PE_RATIO:13.5
95 
ASSET:697.0433
821 
MPS:1.68610113
3 
ROE:20.50% 
EPS:0.159528415 
DPS: 0.030764 
DPR:0.193 
PE_RATIO:10.5
69 
ASSET:813.5028
092 
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2013
-
2014 
MPS:9.43795863
9 
ROE:18.90% 
EPS:0.333722482 
DPS:0.033356 
DPR:0.100 
PE_RATIO:28.2
81 
ASSET:1439.893
262 
MPS:8.73082054
7 
ROE:12.60% 
EPS:0.266010674 
DPS:0.066711 
DPR:0.251 
PE_RATIO:32.8
21 
ASSET:40.01667
779 
MPS:14.0893929
3 
ROE:27.20% 
EPS:0.632421614 
DPS:0.083389 
DPR:0.132 
PE_RATIO:22.2
78 
ASSET:535.4069
38 
MPS:8.73332221
5 
ROE:39.90%  
EPS:0.654269513 
DPS:0.166778 
DPR:0.255 
PE_RATIO:13.3
48 
ASSET:845.5303
536 
MPS:2.35740493
7 
ROE:14.50% 
EPS:0.11724483 
DPS:0.027852 
DPR:0.238 
PE_RATIO:20.1
07 
ASSET:959.0727
151 
2014
-
2015 
MPS:12.5901009
1 
ROE:15.90% 
EPS:0.28063431 
DPS:0.032036 
DPR:0.114 
PE_RATIO:44.8
63 
ASSET:1551.737
947 
MPS:14.8966842
9 
ROE:14.35% 
EPS:0.333173154 
DPS:0.072081 
DPR:0.216 
PE_RATIO:44.7
12 
ASSET:44.08137
114 
MPS:10.2282556
5 
ROE:12.20% 
EPS:0.322761493 
DPS:0.016018 
DPR:0.050  
PE_RATIO:31.6
90 
ASSET:660.7079
93 
MPS:18.3429441 
ROE:33.00% 
EPS:0.710876181 
DPS:0.180202 
DPR:0.253 
PE_RATIO:25.8
03 
ASSET:1275.684
767 
MPS:2.50680762
5 
ROE:15.80% 
EPS:0.132788723 
DPS:0.02675 
DPR:0.201 
PE_RATIO:18.8
78 
ASSET:1014.239
949 
2015
-
2016 
MPS:11.9885291
7 
ROE:19.30% 
EPS:0.377480945 
DPS:0.030186 
DPR:0.080 
PE_RATIO:31.7
59 
ASSET:1635.499
208 
MPS:13.9612104
7 
ROE:17.46% 
EPS:0.440570523 
DPS:0.075466 
DPR:0.171 
PE_RATIO:31.6
89 
ASSET:45.25092
446 
MPS:8.75028299
8 
ROE:4.20% 
EPS:0.11138782 
DPS:0 
DPR:0.000 
PE_RATIO:78.5
57  
ASSET:587.3820
844 
MPS:20.2203607
3 
ROE:56.50% 
EPS:1.545845597 
DPS:0.301864 
DPR:0.195 
PE_RATIO:13.0
80 
ASSET:1367.127
009 
MPS:2.42547732
2 
ROE:15.10% 
EPS:0.140366765 
DPS:0.025206 
DPR:0.180 
PE_RATIO:17.2
80 
ASSET:1276.597
993 
2016
-
2017 
MPS:13.2246376
8 
ROE:19.90% 
EPS:0.500462535 
DPS:0.030836 
DPR:0.062 
PE_RATIO:26.4
25 
ASSET:1882.824
545 
MPS:12.2224791
9 
ROE:12.52% 
EPS:0.372032069 
DPS:0.077089 
DPR:0.207 
PE_RATIO:32.8
53 
ASSET:43.92537
774 
MPS:9.61069996
9 
ROE:8.30% 
EPS:0.237742831 
DPS:0.015418 
DPR:0.065 
PE_RATIO:40.4
25 
ASSET:610.4687
018 
MPS:23.8860622
9 
ROE:23.80% 
EPS:0.850601295 
DPS:0.21585 
DPR:0.254 
PE_RATIO:28.0
81 
ASSET:1495.713
845 
MPS:5.82531606
5 
ROE:13.80% 
EPS:0.160191181 
DPS:0.015418 
DPR:0.096 
PE_RATIO:36.3
65 
ASSET:1448.381
129 
 
Yea
r  
Firm Specific Data of Indian Pharmaceutical Companies 
Annual Financial data in millions of US Dollars 
 
FDC Ltd. India Dabur India  
 
Ajanta 
Pharmaceutical
s 
India  
NATCO 
Pharmaceutical
s  
India 
JB Chem. And 
Pharmaceuticals 
India 
200
7-
200
8 
MPS:0.7141070
54 
ROE:17.90% 
EPS:0.08254127
1 
DPS:0.025013 
MPS:0.8741870
94 
ROE:60.86% 
EPS:0.04827413
7 
DPS:0.018759 
MPS:0.2668834
42 
ROE:17.50% 
EPS:0.06228114
1 
DPS:0.008254 
MPS:0.4239619
81 
ROE:28.30% 
EPS:0.07228614
3 
DPS:0.006253 
MPS:0.862931466 
ROE:10.40% 
EPS:0.134317159 
DPS:0.012506 
DPR:0.093 
PE_RATIO:6.425 
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DPR:0.303 
PE_RATIO:8.6
52 
ASSET:125.537
7689 
DPR:0.389 
PE_RATIO:18.
109 
ASSET:370.385
1926 
DPR:0.133 
PE_RATIO:4.2
85 
ASSET:90.0200
1001 
DPR:0.087 
PE_RATIO:5.8
65 
ASSET:104.902
4512 
ASSET:185.4177089 
200
8-
200
9 
MPS:0.6757557
79 
ROE:21.60% 
EPS:0.08931041
3 
DPS:0.024699 
DPR:0.277 
PE_RATIO:7.5
66 
ASSET:108.911
2824 
MPS:0.9751037
34 
ROE:54.50% 
EPS:0.04465520
6 
DPS:0.017388 
DPR:0.389 
PE_RATIO:21.
836 
ASSET:373.266
1529 
MPS:0.1353487
45 
ROE:17.40% 
EPS:0.05730092
9 
DPS:0.00652 
DPR:0.114 
PE_RATIO:2.3
62 
ASSET:90.7330
5671 
MPS:0.1906737
8 
ROE:24.13% 
EPS:0.06204307
4 
DPS:0.00494 
DPR:0.080 
PE_RATIO:3.0
73 
ASSET:103.932
0292 
MPS:0.502074689 
ROE:5.60% 
EPS:0.06026477 
DPS:0.019759 
DPR:0.328 
PE_RATIO:8.331 
ASSET:148.844102 
200
9-
201
0 
MPS:1.7958728
39 
ROE:31.40% 
EPS:0.17824874
5 
DPS:0.039041 
DPR:0.219 
PE_RATIO:10.
075 
ASSET:152.258
7842 
MPS:1.7691020
64 
ROE:47.60% 
EPS:0.06313441
2 
DPS:0.022309 
DPR:0.353 
PE_RATIO:28.
021 
ASSET:506.190
7418 
MPS:0.5414389
29 
ROE:19.90% 
EPS:0.08633575 
DPS:0.010485 
DPR:0.121 
PE_RATIO:6.2
71 
ASSET:110.451
7568 
MPS:0.5983268
27 
ROE:17.81% 
EPS:0.07718906
9 
DPS:0.008924 
DPR:0.116 
PE_RATIO:7.7
51 
ASSET:123.658
6726 
MPS:1.09180145 
ROE:22.90% 
EPS:0.314110429 
DPS:0.044618 
DPR:0.142 
PE_RATIO:3.476 
ASSET:187.8192973 
201
0-
201
1 
MPS:2.2841100
51 
ROE:26.40% 
EPS:0.18214486
2 
DPS:0.044919 
DPR:0.247 
PE_RATIO:12.
540 
ASSET:172.869
1746 
MPS:2.1572150
48 
ROE:43.20% 
EPS:0.07344188
7 
DPS:0.025828 
DPR:0.352 
PE_RATIO:29.
373 
ASSET:881.055
5867 
MPS:0.5998877
04 
ROE:24.50% 
EPS:0.12981471
1 
DPS:0.015048 
DPR:0.116 
PE_RATIO:4.6
21 
ASSET:117.282
4256 
MPS:1.2282987
09 
ROE:16.25% 
EPS:0.08534531
2 
DPS:0.008984 
DPR:0.105 
PE_RATIO:14.
392 
ASSET:158.854
5761 
MPS:2.061987647 
ROE:22.10% 
EPS:0.370578327 
DPS:0.044919 
DPR:0.121 
PE_RATIO:5.564 
ASSET:224.4581696 
201
1-
201
2 
MPS:1.5356687
27 
ROE:20.40% 
EPS:0.14326366
4 
DPS:0.03925 
DPR:0.274 
PE_RATIO:10.
719 
ASSET:169.325
8758 
MPS:2.0881169
66 
ROE:41.50% 
EPS:0.07261309 
DPS:0.025513 
DPR:0.351 
PE_RATIO:28.
757 
ASSET:824.315
5726 
MPS:1.1936021
98 
ROE:29.30% 
EPS:0.17270140
3 
DPS:0.019625 
DPR:0.114 
PE_RATIO:6.9
11 
ASSET:127.328
0345 
MPS:1.3884800
31 
ROE:14.43% 
EPS:0.08065940
5 
DPS:0.011775 
DPR:0.146 
PE_RATIO:17.
214 
ASSET:177.646
9434 
MPS:1.157688156 
ROE:81.60% 
EPS:1.572171524 
DPS:0.03925 
DPR:0.025 
PE_RATIO:0.736 
ASSET:235.0701599 
201
2-
201
3 
MPS:1.6975223
36 
ROE:21.00% 
EPS:0.15676522
1 
MPS:2.5246384
82 
ROE:40.00% 
EPS:0.08068527
2 
MPS:3.1605415
86 
ROE:32.40% 
EPS:0.23505572
4 
MPS:1.5807313
25 
ROE:14.27% 
EPS:0.08473795
7 
MPS:1.308096159 
ROE:8.00% 
EPS:0.172791747 
DPS:0.055264 
DPR:0.320 
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DPS:0.041448 
DPR:0.264 
PE_RATIO:10.
828 
ASSET:178.004
9737 
DPS:0.027632 
DPR:0.342 
PE_RATIO:31.
290 
ASSET:867.366
6759 
DPS:0.115133 
DPR:0.490 
PE_RATIO:13.
446 
ASSET:132.301
7408 
DPS:0.014737 
DPR:0.174 
PE_RATIO:18.
654 
ASSET:199.023
6714 
PE_RATIO:7.570 
ASSET:239.5136778 
201
3-
201
4 
MPS:2.1005670
45 
ROE:16.60% 
EPS:0.12658439 
DPS:0.037525 
DPR:0.296 
PE_RATIO:16.
594 
ASSET:176.651
1007 
MPS:2.9944963
31 
ROE:38.51% 
EPS:0.08739159
4 
DPS:0.029186 
DPR:0.334 
PE_RATIO:34.
265 
ASSET:885.923
9493 
MPS:6.6819546
36 
ROE:47.40% 
EPS:0.44396264
2 
DPS:0.066711 
DPR:0.150 
PE_RATIO:15.
051 
ASSET:158.338
8926 
MPS:2.6584389
59 
ROE:16.30% 
EPS:0.10723815
9 
DPS:0.016678 
DPR:0.156 
PE_RATIO:24.
790 
ASSET:199.416
2775 
MPS:2.066711141 
ROE:6.00%EPS:0.121
08072 
DPS:0.050033 
DPR:0.413 
PE_RATIO:17.069 
ASSET:225.3168779 
201
4-
201
5 
MPS:2.4291206
15 
ROE:16.00% 
EPS:0.13342944
1 
DPS:0.03604 
DPR:0.270 
PE_RATIO:18.
205 
ASSET:187.746
2758 
MPS:4.2519621
98 
ROE:35.70% 
EPS:0.09738907
6 
DPS:0.032036 
DPR:0.329 
PE_RATIO:43.
660 
ASSET:950.584
6548 
MPS:19.629184
69 
ROE:41.40% 
EPS:0.56447220
9 
DPS:0.096108 
DPR:0.170 
PE_RATIO:34.
774 
ASSET:183.149
127 
MPS:6.7597308
99 
ROE:17.14% 
EPS:0.13022585
3 
DPS:0.016018 
DPR:0.123 
PE_RATIO51.9
08: 
ASSET:221.399
968 
MPS:3.094666026 
ROE:8.90% 
EPS:0.189652411 
DPS:0.064072 
DPR:0.338 
PE_RATIO:16.318 
ASSET:249.463399 
201
5-
201
6 
MPS:2.7960153
95 
ROE:16.10% 
EPS:0.14308354
1 
DPS:0.03396 
DPR:0.237 
PE_RATIO:19.
541 
ASSET:191.049
7321 
MPS:3.7604709
08 
ROE:33.40% 
EPS:0.10746358
8 
DPS:0.03396 
DPR:0.316 
PE_RATIO:34.
993 
ASSET:1046.30
5939 
MPS:21.288959
32 
ROE:39.70% 
EPS:0.71285186 
DPS:0.120746 
DPR:0.169 
PE_RATIO:29.
864 
ASSET:224.586
8236 
MPS:6.2191532
71 
ROE:14.67% 
EPS:0.13734812
5 
DPS:0.018867 
DPR:0.137 
PE_RATIO:45.
280 
ASSET:274.952
8337 
MPS:3.764244208 
ROE:13.50%   
EPS: 0.288129198 
DPS: 0.075466 
DPR: 0.262 
PE_RATIO: 13.064 
ASSET: 248.6906649 
  
  
  
201
6-
201
7 
MPS:3.1467776
75 
ROE:16.00% 
EPS:0.16342892
4 
DPS:0.0346
  
DPR:0.212 
PE_RATIO:19.
255 
ASSET:226.318
2239 
MPS:4.2730496
45 
ROE:28.30% 
EPS:0.11177921
7 
DPS:0.03469 
DPR:0.310 
PE_RATIO:38.
228 
ASSET:1191.95
1896 
MPS:27.139993
83 
ROE:36.70% 
EPS:0.88791242
7 
DPS:0.200432 
DPR:0.226 
PE_RATIO:30.
566 
ASSET:284.875
1156 
MPS:13.058896
08 
ROE:33.00
  
EPS:0.43000308
4 
DPS:0.1040
  
DPR:0.242 
PE_RATIO:30.
369 
ASSET:357.323
4659 
MPS: 5.349984582  
ROE: 14.50% 
EPS: 0.334566759 
DPS: 0.015418  
DPR: 0.046  
PE_RATIO: 15.991   
ASSET: 258.0943571
  
  
 
European Journal of Business and Management                                                                                                                               www.iiste.org 
ISSN 2222-1905 (Paper) ISSN 2222-2839 (Online) 
Vol.11, No.36, 2019 
 
188 
Yea
r  
Firm Specific Data of Indian Pharmaceutical Companies 
Annual Financial data in millions of US Dollars 
 
Nectar Life 
Sciences India 
Indoco Remedies 
India  
RPG Life 
Sciences India  
Albert David 
India  
Aarti Drugs 
India  
2007
-
2008 
MPS:0.50150075 
ROE:29.60% 
EPS:0.124312156 
DPS:0.010005 
DPR:0.080 
PE_RATIO:4.03
4 
ASSET:237.2436
218 
MPS:0.95722861
4 
ROE:11.84% 
EPS:0.081790895 
DPS:0.016758 
DPR:0.205 
PE_RATIO:11.7
03 
ASSET:87.16858
429 
MPS:0.83791895
9 
ROE:12.09% 
EPS:0.104802401 
DPS:0.030015 
DPR:0.286 
PE_RATIO:7.99
5 
ASSET:43.87693
847 
MPS:1.89594797
4 
ROE:15.04% 
EPS:0.32166083 
DPS:0.075038 
DPR:0.233 
PE_RATIO:5.89
4 
ASSET:37.42871
436 
MPS:0.65607803
9 
ROE:13.10% 
EPS:0.146823412 
DPS:0.022511 
DPR:0.153 
PE_RATIO:4.46
8 
ASSET:104.2021
011 
2008
-
2009 
MPS:0.22228808
5 
ROE:18.00% 
EPS:0.068563525 
DPS:0.001976 
DPR:0.029 
PE_RATIO:3.24
2 
ASSET:254.0209
445 
MPS:0.36139102
9 
ROE:11.80% 
EPS:0.06737798 
DPS:0.013831 
DPR:0.205 
PE_RATIO:5.36
4 
ASSET:73.99723
375 
MPS:0.45544358
8 
ROE:12.70% 
EPS:0.090891128 
DPS:0.023711 
DPR0.261 
PE_RATIO:5.01
1 
ASSET:33.18118
949 
MPS:0.92076664
7 
ROE:14.15% 
EPS:0.260620431 
DPS:0.069156 
DPR:0.265 
PE_RATIO:3.53
3 
ASSET:31.88697
886 
MPS:0.37541987
7 
ROE:13.70% 
EPS:0.134755977 
DPS:0.029638 
DPR:0.220 
PE_RATIO:2.78
6 
ASSET:79.66804
979 
2009
-
2010 
MPS:0.80758505
3 
ROE:20.00% 
EPS:0.128276631 
DPS:0.005577 
DPR:0.043 
PE_RATIO:6.29
6 
ASSET:330.2844
395 
MPS:1.18817624
1 
ROE:14.30% 
EPS:0.101952036 
DPS:0.020747 
DPR:0.203 
PE_RATIO:11.6
54 
ASSET:107.1500
279 
MPS:1.63301728
9 
ROE:18.10% 
EPS:0.167540435 
DPS:0.032125 
DPR:0.192 
PE_RATIO:9.74
7 
ASSET:37.49023
982 
MPS:2.66034578
9 
ROE:17.28% 
EPS:0.401561629 
DPS:0.10039  
DPR:0.250 
PE_RATIO:6.62
5 
ASSET:41.26938
09 
MPS1.139542666
: 
ROE:20.90% 
EPS:0.266369214 
DPS:0.055772 
DPR:0.209 
PE_RATIO:4.27
8 
ASSET:93.49693
252 
2010
-
2011 
MPS:0.53677709
2 
ROE:15.50% 
EPS:0.10443571 
DPS:0.002246 
DPR:0.022 
PE_RATIO:5.14
0 
ASSET:407.0971
364 
MPS:1.33295901
2 
ROE:15.50% 
EPS:0.124649074 
DPS:0.024031 
DPR:0.193 
PE_RATIO:10.6
94 
ASSET:126.4907
355 
MPS:1.70353733
9 
ROE:18.30% 
EPS:0.180572712 
DPS:0.035935 
DPR:0.199 
PE_RATIO:9.43
4 
ASSET:42.52891
63 
MPS:2.61875350
9 
ROE:16.19% 
EPS:0.426726558 
DPS:0.101067 
DPR:0.237 
PE_RATIO:6.13
7 
ASSET:44.24031
443 
MPS:1.43739472
2 
ROE:14.80% 
EPS:0.208422235 
DPS:0.056148 
DPR:0.269 
PE_RATIO:6.89
7 
ASSET:115.8674
90 
2011
-
2012 
MPS:0.47198508
5 
ROE:9.70% 
EPS:0.06397802 
DPS:0.001963 
DPR:0.031 
PE_RATIO:7.37
7 
ASSET:416.2300
MPS:1.06172112
6 
ROE:12.60% 
EPS:0.098714552 
DPS:0.021588 
DPR:0.219 
PE_RATIO:10.7
55 
ASSET:128.8195
467 
MPS:1.25404768
9 
ROE:1.10% 
EPS:0.010008831 
DPS:0.0157  
DPR1.569 
PE_RATIO:125.
294 
ASSET:35.82180
MPS:1.63870081
4 
ROE:10.42% 
EPS:0.262388382 
DPS:0.088313 
DPR:0.337 
PE_RATIO:6.24
5 
ASSET:39.80571
092 
MPS:0.99931311
9 
ROE:13.50% 
EPS:0.181925228 
DPS:0.049063 
DPR:0.270 
PE_RATIO:5.49
3 
ASSET:120.2237
European Journal of Business and Management                                                                                                                               www.iiste.org 
ISSN 2222-1905 (Paper) ISSN 2222-2839 (Online) 
Vol.11, No.36, 2019 
 
189 
069 355 268 
2012
-
2013 
MPS:0.28829326
7 
ROE:10.40% 
EPS:0.070369347 
DPS:0.001842 
DPR:0.026 
PE_RATIO:4.09
7 
ASSET:418.9002
487 
MPS:1.06567191
7 
ROE:10.70% 
EPS:0.085474809 
DPS:0.020263 
DPR:0.237 
PE_RATIO:12.4
68 
ASSET:127.4569
402 
MPS:1.14212029
1 
ROE:5.90% 
EPS:0.049184858 
DPS:0.022106 
DPR:0.449 
PE_RATIO:23.2
21 
ASSET:37.90365
663 
MPS:1.66067974
6 
ROE:10.93% 
EPS:0.276319425 
DPS:0.082896 
DPR:0.300 
PE_RATIO:6.01
0 
ASSET:38.60919
223 
MPS:1.31933314
9 
ROE:23.54% 
EPS:0.344109791 
DPS:0.092106 
DPR:0.268 
PE_RATIO:3.83
4 
ASSET:132.5780
60 
2013
-
2014 
MPS:0.40360240
2 
ROE:6.90% 
EPS:0.046197465 
DPS:0.001668 
DPR:0.036 
PE_RATIO:8.73
6 
ASSET:399.2828
552 
MPS:2.35573715
8 
ROE:13.30% 
EPS:0.104903269 
DPS:0.023349 
DPR:0.223 
PE_RATIO:22.4
56 
ASSET:121.6477
652 
MPS:1.00233489 
ROE:52.90% 
EPS:0.538525684 
DPS:0.020013 
DPR:0.037 
PE_RATIO:1.86
1 
ASSET:32.70013
342 
MPS:1.93462308
2 
ROE:14.66% 
EPS:0.367411608 
DPS:0.083389 
DPR:0.227 
PE_RATIO:5.26
6 
ASSET:33.02201
468 
MPS:2.19646431 
ROE:26.90% 
EPS:0.424949967 
DPS:0.10840 
DPR:0.255 
PE_RATIO:5.16
9 
ASSET:141.7111
40 
2014
-
2015 
MPS:0.59106198
9 
ROE:7.20% 
EPS:0.047252923 
DPS:0.001602 
DPR:0.034 
PE_RATIO:12.5
08 
ASSET:389.1878
904 
MPS:5.81611404
8 
ROE:16.80% 
EPS:0.14400128 
DPS:0.025629 
DPR:0.178 
PE_RATIO:40.3
89 
ASSET:131.3951
626 
MPS:2.64936729
1 
ROE:0.80% 
EPS:0.009610764 
DPS:0.012814 
DPR:1.333 
PE_RATIO:275.
667 
ASSET:31.54092
58 
MPS:4.40333173
2 
ROE:15.00% 
EPS:0.384590742 
DPS:0.088099 
DPR:0.229  
PE_RATIO:11.4
49 
ASSET:30.98670
511 
MPS:10.4396924
6 
ROE:27.60% 
EPS:0.510972289 
DPS:0.128144 
DPR:0.251 
PE_RATIO:20.4
31 
ASSET:160.4837
41 
2015
-
2016 
MPS:0.57354162 
ROE:5.80% 
EPS:0.036525545 
DPS:0.001509 
DPR:0.041 
PE_RATIO:15.7
02 
ASSET:385.8274
847 
MPS:4.34533242
8 
ROE:14.80% 
EPS:0.134178553 
DPS:0.024149 
DPR:0.180 
PE_RATIO:32.3
85 
ASSET:141.9666
44 
MPS:3.35672779
4 
ROE:9.20% 
EPS:0.1061052 
DPS:0.02414 
DPR:0.228 
PE_RATIO:31.6
36 
ASSET:31.41196
891 
MPS:4.50984831
3 
ROE:41.80% 
EPS:1.269338163 
DPS:0.083013 
DPR:0.065 
PE_RATIO:3.55
3 
ASSET:33.78462
003 
MPS:6.85985963
3 
ROE:21.00% 
EPS:0.428345031 
DPS:0.101879 
DPR:0.238 
PE_RATIO:16.0
15  
ASSET:168.3948
381 
2016
-
2017 
MPS:0.54270737 
ROE:5.60% 
EPS:0.038082023 
DPS:0.000771 
DPR:0.020 
PE_RATIO:14.2
51 
ASSET:397.9185
939 
MPS:3.85368486 
ROE:12.60% 
EPS:0.128893 
DPS:0.024669 
DPR:0.191 
PE_RATIO:29.8
98 
ASSET:184.5050
879 
MPS:6.93493678
7 
ROE:15.35% 
EPS:0.195806352 
DPS:0.04317 
DPR:0.220 
PE_RATIO:35.4
17 
ASSET:38.06506
321 
MPS:4.9128893 
ROE:9.98% 
EPS0.431082331: 
DPS:0.084798 
DPR:0.197 
PE_RATIO:11.3
97 
ASSET:43.86833
179 
MPS:8.87372803 
ROE:21.90% 
EPS:0.514955288 
DPS:0.015418 
DPR:0.030 
PE_RATIO:17.2
32 
ASSET:183.6262
72 
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Firm Specific Data of US and European Pharmaceutical Companies 
Annual Financial data in millions of US Dollars 
 
Pfizer INC 
(USA) 
Merck & Co. 
INC (USA) 
 
Eli Lily & 
Company (USA)  
Bristol-Myers 
Squibb Company 
(USA)  
Abbott 
Laboratories 
(USA)  
2008 MPS:17.71 
ROE:13.22% 
EPS:1.2 
DPS:1.28 
DPR:1.067 
PE_RATIO:14.7
58 
ASSET:111148 
MPS:30.4 
ROE:42.30% 
EPS:3.65 
DPS:1.52 
DPR:0.416 
PE_RATIO:8.32
9 
ASSET:47196 
MPS40.27: 
ROE:-20.50% 
EPS:-1.89 
DPS:1.9 
DPR:-1.005 
PE_RATIO:-
21.307 
ASSET;29123 
MPS:23.25 
ROE:54.57% 
EPS:2.56 
DPS:1.24 
DPR:0.484 
PE_RATIO:9.082 
ASSET:29486 
MPS:25.54 
ROE:27.68% 
EPS:3.16 
DPS:1.44 
DPR:0.456 
PE_RATIO:8.082 
ASSET:42419 
2009 MPS:18.19 
ROE:11.70% 
EPS:1.23 
DPS:0.8 
DPR:0.650 
PE_RATIO:14.7
89 
ASSET:212949 
MPS:36.54 
ROE:33.20% 
EPS:5.67 
DPS:1.52 
DPR:0.268 
PE_RATIO:6.44
4 
ASSET:112314 
MPS:35.71 
ROE:53.20% 
EPS:3.94 
DPS:1.96 
DPR:0.497 
PE_RATIO:9.06
3 
ASSET:27461 
MPS:25.25 
ROE:78.05%  
EPS:5.35 
DPS:1.25 
DPR:0.234 
PE_RATIO:4.720 
ASSET:31008 
MPS:25.83 
ROE:28.30% 
EPS:3.71 
DPS:1.6 
DPR:0.431 
PE_RATIO:6.962 
ASSET:52582 
2010 MPS:17.15 
ROE:9.28% 
EPS:1.03 
DPS:0.72 
DPR:0.699 
PE_RATIO:16.6
50 
ASSET:195014 
MPS:36.04 
ROE:1.50% 
EPS:0.28 
DPS:1.52 
DPR:5.429 
PE_RATIO:128.
71 
ASSET:105781 
MPS:35.04 
ROE:46.20% 
EPS:4.58 
DPS:1.96 
DPR:0.428 
PE_RATIO:7.65
1 
ASSET:31001 
MPS:26.48 
ROE:20.30% 
EPS:1.8 
DPS:1.29 
DPR:0.717 
PE_RATIO:14.71
1 
ASSET:31076  
MPS:22.92 
ROE:20.20% 
EPS:2.99 
DPS:1.76 
DPR:0.589 
PE_RATIO:7.666 
ASSET:60574 
2011 MPS:21.64 
ROE:11.77% 
EPS:1.28 
DPS:0.8 
DPR:0.625 
PE_RATIO:16.9
06 
ASSET:188002 
MPS:37.7 
ROE:11.50% 
EPS:2.04 
DPS:1.52 
DPR:0.745 
PE_RATIO:18.4
80 
ASSET:105128 
MPS:41.56 
ROE:33.50% 
EPS:3.9 
DPS:1.96 
DPR:0.503 
PE_RATIO:10.6
56 
ASSET:33660 
MPS:35.24 
ROE:23.40% 
EPS:2.18 
DPS:1.33 
DPR:0.610 
PE_RATIO:16.16
5 
ASSET:32970 
MPS:26.9 
ROE:20.06% 
EPS:3.04 
DPS:1.92 
DPR:0.632 
PE_RATIO:8.849 
ASSET60277: 
2012 MPS:25.08 
ROE:12.24% 
EPS:1.96 
DPS:0.88 
DPR:0.449 
PE_RATIO:12.7
96 
ASSET:185798 
MPS:40.94 
ROE:11.50% 
EPS:2.03 
DPS:1.68 
DPR:0.828 
PE_RATIO:20.1
67 
ASSET:106132 
MPS:49.32 
ROE:28.90% 
EPS:3.67 
DPS:1.96 
DPR:0.534 
PE_RATIO:13.4
39 
ASSET:34399 
MPS:32.59 
ROE13.30%: 
EPS:1.17 
DPS:1.37 
DPR:1.171 
PE_RATIO:27.85
5 
ASSET:35897 
MPS:31.34 
ROE:23.31% 
EPS:3.79 
DPS:2.01 
DPR:0.530 
PE_RATIO:8.269 
ASSET:67235 
2013 MPS:30.63 
ROE:27.92% 
EPS:3.23 
DPS:0.96 
DPR:0.297 
PE_RATIO:9.48
3 
MPS:50.05 
ROE:8.60% 
EPS:1.49 
DPS:1.72 
DPR:1.154 
PE_RATIO:33.5
91 
MPS:51 
ROE:28.90% 
EPS:4.33 
DPS:1.96 
DPR:0.453 
PE_RATIO:11.7
78 
MPS:53.15 
ROE:17.80% 
EPS:1.56 
DPS:1.4 
DPR:0.897 
PE_RATIO:34.07
1 
ASSET:38592 
MPS:38.33 
ROE:9.92% 
EPS:1.65 
DPS:0.56 
DPR:0.339 
PE_RATIO:23.23
0 
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ASSET:172101 ASSET:105645 ASSET:35249 ASSET:42935 
2014 MPS:31.15 
ROE:12.37% 
EPS:1.44 
DPS:1.04 
DPR:0.722 
PE_RATIO:21.6
32 
ASSET:167566 
MPS:56.79 
ROE:24.20% 
EPS:4.12 
DPS:1.76 
DPR:0.427 
PE_RATIO:13.7
84 
ASSET:98335 
MPS:68.99 
ROE:14.50% 
EPS:2.23 
DPS:1.96 
DPR:0.879 
PE_RATIO:30.9
37 
ASSET:36308 
MPS:59.03 
ROE:13.40%  
EPS:1.21 
DPS:1.44 
DPR:1.190 
PE_RATIO:48.78
5  
ASSET:33749 
MPS:45.02 
ROE:9.78% 
EPS:1.51 
DPS:0.9 
DPR:0.596 
PE_RATIO:29.81
5 
ASSET:41207 
2015 MPS:32.28 
ROE:10.23% 
EPS:1.13 
DPS:1.12 
DPR:0.991 
PE_RATIO:28.5
66 
ASSET:167381 
MPS:52.82 
ROE:9.50% 
EPS:1.58 
DPS:1.8 
DPR:1.139 
PE_RATIO:33.4
30 
ASSET:101677 
MPS:84.26 
ROE:16.10% 
EPS:2.27 
DPS:2 
DPR:0.881 
PE_RATIO:37.1
19 
ASSET:35569 
MPS:68.79 
ROE:10.70% 
EPS:0.94 
DPS:1.48 
DPR:1.574 
PE_RATIO:73.18
1 
ASSET:31748 
MPS:44.91 
ROE:20.69% 
EPS:2.96 
DPS:0.96 
DPR:0.324 
PE_RATIO:15.17
2 
ASSET:41247 
2016 MPS:32.48 
ROE:11.61% 
EPS:1.18 
DPS:1.2 
DPR:1.017 
PE_RATIO:27.5
25 
ASSET:171615 
MPS:58.87 
ROE:9.20% 
EPS:1.42 
DPS:1.84 
DPR:1.296 
PE_RATIO:41.4
58 
ASSET:95377 
MPS:73.55 
ROE:19.20% 
EPS:2.59 
DPS:2.04 
DPR:0.788 
PE_RATIO:28.3
98 
ASSET:38806 
MPS:58.44 
ROE:29.30% 
EPS:2.67 
DPS:1.52 
DPR:0.569 
PE_RATIO:21.88
8 
ASSET:33707 
MPS38.41: 
ROE:6.70% 
EPS:0.95 
DPS:1.04 
DPR:1.095 
PE_RATIO:40.43
2 
ASSET:52666 
2017 MPS:36.22 
ROE:32.56% 
EPS:3.57 
DPS:1.28 
DPR:0.359 
PE_RATIO:10.1
46 
ASSET:171797 
MPS:56.27 
ROE:6.43% 
EPS:0.88 
DPS:1.88 
DPR:2.136 
PE_RATIO:63.9
43 
ASSET:87872 
MPS:84.46 
ROE:-1.59% 
EPS:-0.19 
DPS:2.08 
DPR:-10.947 
PE_RATIO:-
444.526 
ASSET:44981 
MPS:61.28 
ROE:7.21% 
EPS:0.61 
DPS:1.56 
DPR:2.557 
PE_RATIO:100.4
59  
ASSET:33551 
MPS:57.07 
ROE:1.85% 
EPS:0.27 
DPS:1.06 
DPR:3.926 
PE_RATIO:211.3
70 
ASSET:76250 
 
 
Yea
r  
Firm Specific Data of US and European Pharmaceutical Companies 
Annual Financial data in millions of US Dollars 
 
Akorn INC 
(USA) 
OPKO Health 
(USA)  
Biogen INC 
(USA)  
AMAG 
Pharmaceutical
s (USA)  
BioMarin 
Pharmaceutical 
(USA)  
2008 MPS:2.3 
ROE:-12.60% 
EPS:-0.09 
DPS:0 
DPR:0.000  
PE_RATIO:-
25.556 
ASSET:82.3 
MPS:1.62 
ROE:-464.70% 
EPS:-0.21 
DPS:0 
DPR:0.000 
PE_RATIO:-7.714 
ASSET:21.8 
MPS:47.63 
ROE:13.80% 
EPS:2.67 
DPS:0 
DPR:0.000 
PE_RATIO:17.
839 
ASSET:8479 
MPS:35.85 
ROE-28.70%
 : 
EPS:-4.22 
DPS:0 
DPR:0.000 
PE_RATIO:-
8.495 
ASSET:232 
MPS:17.8 
ROE:13.27% 
EPS:0.31 
DPS:0 
DPR:0.000 
PE_RATIO:57.4
19 
ASSET:906.7 
2009 MPS:1.79 
ROE:-50.60% 
MPS:1.83 
ROE:-103.70% 
MPS:53.5 
ROE:16.10% 
MPS:38.03 
ROE:-52.40% 
MPS:18.81 
ROE:-0.16% 
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EPS:-0.28 
DPS:0 
DPR:0.000 
PE_RATIO:-
6.393 
ASSET:68.8 
EPS:-0.15 
DPS:0 
DPR:0.00 
PE_RATIO:-
12.200 
ASSET:87.4 
EPS:3.37 
DPS:0 
DPR:0.000 
PE_RATIO:15.
875 
ASSET:8552 
EPS:-5.46 
DPS:0 
DPR:0.000 
PE_RATIO:-
6.965 
ASSET:184.6 
EPS:0 
DPS:0 
DPR:#DIV/0! 
PE_RATIO:#DI
V/0! 
ASSET:917.2 
2010 MPS:6.07 
ROE:34.80% 
EPS:0.24 
DPS:0 
DPR:0.000 
PE_RATIO:25.2
92 
ASSET:111.1 
MPS:3.67 
ROE:-35.66% 
EPS:-0.08 
DPS:0 
DPR:0.00 
PE_RATIO:-
45.875 
ASSET:77.8 
MPS:67.05 
ROE:17.30% 
EPS:3.98 
DPS:0 
DPR:0.000 
PE_RATIO:16.
847 
ASSET:8092 
MPS:18.1 
ROE:-41.80% 
EPS:-3.9 
DPS:0 
DPR:0.000 
PE_RATIO:-
4.641 
ASSET:336.1 
MPS:26.93 
ROE:39.57% 
EPS:2 
DPS:0 
DPR:0.000 
PE_RATIO:13.4
65 
ASSET:1262.6 
2011 MPS:11.12 
ROE:35.10% 
EPS:0.45 
DPS:0 
DPR:0.000 
PE_RATIO:24.7
11 
ASSET:307.1 
MPS:4.9 
ROE:-1.11% 
EPS:-0.01 
DPS:0 
DPR:0.000 
PE_RATIO:-
490.000 
ASSET:229.5 
MPS:110.05 
ROE:20.90% 
EPS:5.09 
DPS:0 
DPR:0.000 
PE_RATIO:21.
621 
ASSET:9050 
MPS:18.91 
ROE:-36.20% 
EPS:-3.64 
DPS:0 
DPR:0.000 
PE_RATIO:-
5.195 
ASSET:267.2 
MPS:34.38 
ROE:-7.22% 
EPS:-0.48 
DPS:0 
DPR:0.000 
PE_RATIO:-
71.625 
ASSET:1305.7 
2012 MPS:13.36 
ROE:19.70% 
EPS:0.37 
DPS:0 
DPR:0.000  
PE_RATIO:36.1
08  
ASSET:369.6 
MPS:4.81 
ROE:-14.87% 
EPS:-0.11 
DPS:0 
DPR:0.000 
PE_RATIO:-
43.727 
ASSET:289.8 
MPS:146.37 
ROE:20.60% 
EPS:5.8 
DPS:0 
DPR:0.000 
PE_RATIO:25.
236 
ASSET:10130 
MPS:14.71 
ROE:-9.50% 
EPS:-0.78 
DPS:0 
DPR:0.000 
PE_RATIO:-
18.859 
ASSET:258.1 
MPS:49.2 
ROE:-12.78% 
EPS:-0.95 
DPS:N/A 
DPR:#VALUE! 
PE_RATIO:-
51.789 
ASSET:1568.3 
2013 MPS:24.62 
ROE:22.70% 
EPS:0.54 
DPS:0 
DPR:0.000 
PE_RATIO:45.5
93 
ASSET:431.8 
MPS:8.44 
ROE:-21.20%  
EPS:-0.32 
DPS:0 
DPR:0.000 
PE_RATIO:-
26.375 
ASSET:1391.5 
MPS:279.57 
ROE:23.90% 
EPS:7.86 
DPS:N/A 
DPR:#VALUE! 
PE_RATIO:35.
569 
ASSET:11863 
MPS:24.28 
ROE:-5.60% 
EPS:-0.44 
DPS:N/A 
DPR:#VALUE! 
PE_RATIO:-
55.182  
ASSET:265.5 
MPS:70.35 
ROE:-14.97%  
EPS:-1.28 
DPS:N/A 
DPR:#VALUE!  
PE_RATIO:-
54.961 
ASSET:2244.1 
2014 MPS:36.2 
ROE:4.70% 
EPS:0.13 
DPS:0 
DPR:0.000 
PE_RATIO:278.
462 
ASSET:1893.9 
MPS:9.99 
ROE:-20.00% 
EPS:-0.41 
DPS:0 
DPR:0.000 
PE_RATIO:-
24.366 
ASSET:-24.366 
MPS:339.45 
ROE:30.20% 
EPS:12.42 
DPS:N/A 
DPR:#VALUE! 
PE_RATIO:27.
331 
ASSET:14315 
MPS:42.62 
ROE:42.97% 
EPS:6.06 
DPS:N/A 
DPR:#VALUE!
  
PE_RATIO:7.0
33 
ASSET:1388.9 
MPS:90.4 
ROE:-9.30% 
EPS:-0.92 
DPS:N/A 
DPR:#VALUE! 
PE_RATIO:-
98.261 
ASSET:2475.4 
2015 MPS:37.31 
ROE:30.80% 
EPS:1.29 
DPS:0 
DPR:0.000 
PE_RATIO:28.9
22 
MPS:10.05 
ROE:-2.10% 
EPS:-0.06 
DPS:0 
DPR:0.000 
PE_RATIO:-
167.500 
MPS:306.35 
ROE:35.20% 
EPS:15.37 
DPS:0 
DPR:0.000 
PE_RATIO:19.
932 
MPS:30.19 
ROE:4.71% 
EPS:1.04 
DPS:N/A 
DPR:#VALUE! 
PE_RATIO:29.
029 
MPS:104.76 
ROE:-8.70% 
EPS:-1.07 
DPS:N/A 
DPR:#VALUE!  
PE_RATIO:-
97.907 
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ASSET:2042.5 ASSET:2799.2 ASSET:19505 ASSET:2476.2 ASSET:3729.4 
2016 MPS:21.83 
ROE:25.60% 
EPS:1.5 
DPS:N/A 
DPR:#VALUE! 
PE_RATIO:14.5
53 
ASSET:1973.7 
MPS:9.3 
ROE:-2.40% 
EPS:-0.09 
DPS:N/A 
DPR:#VALUE! 
PE_RATIO:#VAL
UE! 
ASSET:2766.6 
MPS:283.58 
ROE:34.40% 
EPS:16.95 
DPS:0 
DPR:0.000 
PE_RATIO:16.
730 
ASSET:22877 
MPS:34.8 
ROE:0.26% 
EPS:-0.07 
DPS:N/A 
DPR:#VALUE! 
PE_RATIO:-
497.143 
ASSET:2478.4 
MPS:82.84 
ROE:-24.40% 
EPS:-3.8 
DPS:N/A 
DPR:#VALUE! 
PE_RATIO:-
21.800 
ASSET:-21.800 
2017 MPS:32.23 
ROE:-2.97% 
EPS:-0.2 
DPS:N/A 
DPR:#VALUE! 
PE_RATIO:-
161.150 
ASSET:1909.5 
MPS:4.9 
ROE:-15.50% 
EPS:-0.55 
DPS:N/A 
DPR:#VALUE! 
PE_RATIO:-8.909 
ASSET:2590 
MPS:318.57 
ROE:20.51% 
EPS:11.94 
DPS:N/A 
DPR:#VALUE! 
PE_RATIO:26.
681 
ASSET:23653 
MPS:13.25 
ROE:-23.10%
  
EPS:-5.71 
DPS:N/A 
DPR:#VALUE! 
PE_RATIO:-
2.320 
ASSET:1900.4 
MPS:89.17 
ROE:-4.19% 
EPS:-0.67 
DPS:N/A 
DPR:#VALUE! 
PE_RATIO:-
133.090 
ASSET:4633.1 
 
Year
  
Firm Specific Data of US and European Pharmaceutical Companies 
Annual Financial data in millions of US Dollars 
 
Sanofi SA 
(France) 
Roche Holdings 
(Switzerland)  
IPSEN SA 
(France) 
 
Bayer AG 
(Germany) 
 
NICOX SA 
(France) 
 
2008 MPS:32.66076 
ROE:8.61% 
EPS:2.115036 
DPS:1.58268 
DPR:0.748  
PE_RATIO:15.4
42 
ASSET:51787.44
78 
MPS:179.51367 
ROE:19.90% 
EPS:11.098563 
DPS:5.3205 
DPR:0.479  
PE_RATIO:0.47
9 
ASSET:80966.30
49 
MPS:20.136006 
ROE:17.41% 
EPS:1.25895 
DPS:0.50358 
DPR:0.400  
PE_RATIO:15.994 
ASSET:1125.4293
6 
MPS:39.617358 
ROE:10.41% 
EPS:1.589874 
DPS:0.992772 
DPR:0.624  
PE_RATIO:24.9
19 
ASSET:37776.41
34 
MPS:24.078318 
ROE:-54.50% 
EPS:-4.841562 
DPS:0 
DPR:0.000
  
PE_RATIO:-
4.973 
ASSET:88.9178
4 
2009 MPS:38.37682 
ROE:11.30%  
EPS:2.80891 
DPS:1.6728 
DPR:0.596  
PE_RATIO:13.6
63 
ASSET:55934.94
7 
MPS:187.0816 
ROE:30.00% 
EPS:9.374752 
DPS:6.2016 
DPR:0.662  
PE_RATIO:19.9
56 
ASSET:77070.38
4 
MPS:27.01572 
ROE:16.76% 
EPS:1.29642 
DPS:0.52275 
DPR:0.403  
PE_RATIO:20.839 
ASSET:1099.0993 
MPS:39.08776 
ROE:7.70% 
EPS:1.16399 
DPS:0.96186 
DPR:0.826  
PE_RATIO:33.5
81 
ASSET:35576.27
4 
MPS:0.30361 
ROE:-49.30% 
EPS:-4.18897 
DPS:0 
DPR:0.000
  
PE_RATIO:-
4.847 
ASSET:109.707
8 
2010 MPS:35.66739 
ROE:10.80% 
EPS:3.123226 
DPS:1.8635 
MPS:133.10388 
ROE:103.00% 
EPS:9.451494 
DPS:6.15186 
MPS:17.024936 
ROE:9.25% 
EPS:0.842302 
DPS:0.59632 
MPS:41.22062 
ROE:6.90% 
EPS:1.15537 
DPS:1.103192 
MPS:8.1994 
ROE:-36.10% 
EPS:-2.258562 
DPS:0 
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DPR:0.597  
PE_RATIO:11.4
20 
ASSET:63555.78
56 
DPR:0.651  
PE_RATIO:14.0
83 
ASSET:56876.74
2 
DPR:0.708  
PE_RATIO:20.212 
ASSET:1250.9302
8 
DPR:0.955  
PE_RATIO:35.6
77 
ASSET:38392.57
24 
DPR:0.000
  
PE_RATIO:-
3.630 
ASSET:84.1556
6 
2011 MPS:43.862075 
ROE:10.40% 
EPS:3.331199 
DPS:2.048185 
DPR:0.615  
PE_RATIO:13.1
67 
ASSET:77806.29
72 
MPS:156.62066 
ROE:86.60% 
EPS:10.3411  
DPS:6.39268  
DPR:0.618  
PE_RATIO:15.1
45 
ASSET:57891.35
8 
MPS:18.742825 
ROE:0.04% 
EPS:0.007729 
DPS:0.61832 
DPR:80.000  
PE_RATIO:2425.0
00 
ASSET:1263.4596
3 
MPS:38.18126 
ROE:13.00% 
EPS:2.272326 
DPS:1.252098 
DPR:0.551  
PE_RATIO:16.8
03 
ASSET:40767.38
34 
MPS:3.9224675 
ROE:-18.00%
  
EPS:-0.881106 
DPS:0 
DPR:0.000
  
PE_RATIO:-
4.452 
ASSET:74.0438
2 
2012 MPS:54.149315 
ROE:8.60% 
EPS:2.85196 
DPS:2.101045 
DPR:0.737  
PE_RATIO:18.9
87 
ASSET:76160.22
65 
MPS:171.16302 
ROE:70.80% 
EPS:10.183696 
DPS:6.73113 
DPR:0.661  
PE_RATIO:16.8
08 
ASSET:59351.16
64 
MPS:17.271045 
ROE:-2.93% 
EPS:-0.25789 
DPS:0.6068 
DPR:-2.353 
  
PE_RATIO:-
66.971 
ASSET:1184.7011
5 
MPS:54.528565 
ROE:12.80% 
EPS:2.1693 
DPS:1.418395 
DPR:0.654  
PE_RATIO:25.1
36 
ASSET:38924.70 
MPS:8.836525 
ROE:-12.90% 
EPS:-0.53095 
DPS:0 
DPR:0.000
  
PE_RATIO:-
16.643 
ASSET:63.7898 
2013 MPS:56.012256 
ROE:6.50% 
EPS:2.040903 
DPS:2.03364 
DPR:0.996  
PE_RATIO:27.4
45 
ASSET:69764.74
65 
MPS:220.45814 
ROE:66.00% 
EPS:11.735787 
DPS:6.95058 
DPR:0.592  
PE_RATIO:18.7
85 
ASSET:55397.01
37 
MPS:24.962931 
ROE:16.27% 
EPS1.336392: 
DPS:0.58104 
DPR:0.435  
PE_RATIO:18.679 
ASSET:1136.8773
9 
MPS:74.046285 
ROE:16.30% 
EPS:2.75994 
DPS:1.503441 
DPR:0.545  
PE_RATIO:26.8
29 
ASSET:37271.53
71 
MPS:8.7192315 
ROE:-26.69%
  
EPS:-0.900612 
DPS:0 
DPR:0.000
  
PE_RATIO:-
9.681 
ASSET:52.4388
6 
2014 MPS:54.89133 
ROE:7.76% 
EPS:2.42317 
DPS:2.067675 
DPR:0.853  
PE_RATIO:22.6
53 
ASSET:70657.89
6 
MPS:264.8583 
ROE:48.00% 
EPS:10.871308 
DPS:7.9136 
DPR:0.728  
PE_RATIO:24.3
63 
ASSET:74724.16
8 
MPS:31.1965  
ROE:15.07% 
EPS:1.356685 
DPS:0.616675 
DPR:0.455  
PE_RATIO:22.995 
ASSET:1242.9991
5 
MPS:81.9815 
ROE:16.30% 
EPS:2.96004 
DPS:1.603355 
DPR:0.542  
PE_RATIO:27.6
96 
ASSET:50954.76
7 
MPS:6.7580325 
ROE:-29.31% 
EPS:-1.037465 
DPS:0 
DPR:0.000
  
PE_RATIO:-
6.514 
ASSET:108.825 
2015 MPS:72.16266 
ROE:7.50% 
EPS:3.011368 
DPS:2.690033 
DPR:0.893  
PE_RATIO:23.9
63 
MPS:275.006475 
ROE:43.70% 
EPS:10.344417 
DPS:8.04897 
DPR:0.778  
PE_RATIO:26.5
85 
MPS:56.0041 
ROE:16.59% 
EPS:2.120811 
DPS:0.780385 
DPR:0.368  
PE_RATIO:26.407 
MPS:106.31598 
ROE:18.52% 
EPS:4.489509 
DPS:2.258526 
DPR:0.503  
PE_RATIO:23.6
81 
MPS:8.3767444 
ROE:-28.22% 
EPS:-1.147625 
DPS:0 
DPR:0.000
  
PE_RATIO:-
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ASSET:93940.91
01 
ASSET:75285.69
31 
ASSET:1779.2778 ASSET:67863.19
77 
7.299 
ASSET:149.925
73 
2016 MPS:72.8243 
ROE:8.14% 
EPS:3.46602 
DPS:2.80312 
DPR:0.809  
PE_RATIO:21.0
11 
ASSET:99131.01
3 
MPS:242.2364 
ROE:42.70% 
EPS:11.440072 
DPS:8.34596 
DPR:0.730  
PE_RATIO:21.1
74 
ASSET:78186.37
82 
MPS:65.0589 
ROE:17.50% 
EPS:2.59478 
DPS:0.80495 
DPR:0.310  
PE_RATIO:25.073 
ASSET:2295.0545 
MPS:92.37985 
ROE:16.59% 
EPS:5.07592 
DPS:2.51902 
DPR:0.496  
PE_RATIO:18.2
00 
ASSET:77879.38 
MPS:8.078857 
ROE:-18.48% 
EPS:-0.7576
  
DPS:0.000 
DPR:0.000
  
PE_RATIO: -
10.664 
ASSET:140.818
9 
2017 MPS:59.93727 
ROE:14.55% 
EPS:5.58914 
DPS:2.527626 
DPR:0.452  
PE_RATIO:10.7
24 
ASSET:83264.00
46 
MPS:240.1681 
ROE:34.29% 
EPS:9.8720 
DPS:8.09665 
DPR:0.820  
PE_RATIO:24.3
28 
ASSET:74797.43
8 
MPS:83.061294 
ROE:18.75% 
EPS:2.75286 
DPS:0.8342 
DPR:0.303  
PE_RATIO:30.173 
ASSET:2562.6624 
MPS:85.38037 
ROE:21.85% 
EPS:6.915518 
DPS:2.302392 
DPR:0.333  
PE_RATIO:12.3
46 
ASSET:62637.57
54 
MPS:8.458788 
ROE:-3.12% 
EPS:-0.100104 
DPS:0 
DPR:0.000
  
PE_RATIO:-
84.500 
ASSET:125.797
36 
 
Yea
r  
Firm Specific Data of US and European Pharmaceutical Companies 
Annual Financial data in millions of US Dollars 
 
Alliance 
Pharmaceuticals 
(UK) 
Virbac SA 
(France) 
 
Vifor AG 
(Switzerland) 
 
Novartis AG 
(Switzerland) 
 
Astra Zenica PLC 
(UK) 
 
2008 MPS:1.8209 
ROE:31.25% 
EPS:0.0139 
DPS:0 
DPR:0.000  
PE_RATIO:131.0
00 
ASSET:33.916 
MPS:41.682036 
ROE:18.63% 
EPS:2.956734 
DPS:0.86328 
DPR0.292:  
PE_RATIO:14.0
97 
ASSET:296.8963
8 
MPS:36.530553 
ROE:35.10% 
EPS:3.096531 
DPS:0.74487 
DPR:0.241
  
PE_RATIO:11.
797 
ASSET:2236.31
256 
MPS:56.07807 
ROE:16.47% 
EPS:4.0978491 
DPS:2.138841 
DPR:0.522  
PE_RATIO:13.6
85 
ASSET:88650.31
572 
MPS:1909.86 
ROE:39.80% 
EPS:2.02245 
DPS:0.9869 
DPR:0.488  
PE_RATIO:944.3
30 
ASSET:22678.023
75 
2009 MPS:16.4035 
ROE:32.30% 
EPS:0.01238 
DPS:0 
DPR:0.000  
PE_RATIO:1325.
000 
ASSET:35.1592 
MPS:50.69281 
ROE:17.96% 
EPS:3.12256 
DPS:0.92004 
DPR:0.295  
PE_RATIO:16.2
34 
ASSET:302.8465 
MPS:38.76 
ROE:31.20% 
EPS:3.338528 
DPS:0.7752 
DPR:0.232
  
PE_RATIO:11.
610 
ASSET:3003.95
168 
MPS:58.34672 
ROE:15.60% 
EPS:3.948352 
DPS:2.149888 
DPR:0.545  
PE_RATIO:14.7
77 
ASSET:101971.5
289 
MPS:1796.0285 
ROE:41.10% 
EPS:1.98699 
DPS:0.87898 
DPR:0.442  
PE_RATIO:903.8
94 
ASSET: 
21043.20212 
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2010 MPS:19.778 
ROE:34.00% 
EPS:0.02552 
DPS:0.00638 
DPR:0.250  
PE_RATIO:775.0
00 
ASSET:49.3812 
MPS:96.902 
ROE:23.74% 
EPS:5.456328 
DPS:1.1181 
DPR:0.205  
PE_RATIO:17.7
60 
ASSET:397.8945
2 
MPS:52.66365 
ROE:27.40% 
EPS:3.290313 
DPS:0.74568 
DPR:0.227
  
PE_RATIO:16.
006 
ASSET:2805.06
174 
MPS:51.218895 
ROE:16.20% 
EPS:3.709758 
DPS:2.041299 
DPR:0.550  
PE_RATIO:13.8
07 
ASSET:107139.9
549 
MPS:1864.236 
ROE:36.70% 
EPS:2.27766 
DPS:1.03356 
DPR:0.454  
PE_RATIO:818.4
87 
ASSET:22846.158
59 
2011 MPS:19.94202 
ROE:21.50% 
EPS:0.02584 
DPS:0.00646 
DPR:0.250  
PE_RATIO:771.7
50 
ASSET:53.1658 
MPS:92.67071 
ROE:19.47% 
EPS:5.278907 
DPS:1.352575 
DPR:0.256  
PE_RATIO:17.5
55 
ASSET:454.9289
4 
MPS:51.658495 
ROE:21.80% 
EPS:3.252746 
DPS:0.84609
  
DPR:0.260
  
PE_RATIO:15.
882 
ASSET:2930.76
175 
MPS:50.48337 
ROE:14.10% 
EPS:3.38436  
DPS:2.105824 
DPR:0.622  
PE_RATIO:14.9
17 
ASSET:103841.5
47 
MPS:1921.85 
ROE:42.70% 
EPS:3.0362 
DPS:1.1628 
DPR:0.383  
PE_RATIO:632.9
79 
ASSET:22046.804
28 
2012 MPS:19.6215 
ROE:18.10% 
EPS:0.02472 
DPS:0.00618 
DPR:0.250  
PE_RATIO:793.7
50 
ASSET:62.1708 
MPS:113.661225 
ROE:20.24% 
EPS:5.999735 
DPS:1.44115 
DPR:0.240  
PE_RATIO:18.9
44 
ASSET:627.8104
5 
MPS:48.58319 
ROE:21.00% 
EPS:3.608252 
DPS:1.00738 
DPR:0.279
  
PE_RATIO:13.
464 
ASSET:2886.96
792 
MPS:52.61271 
ROE:13.70% 
EPS:3.2053 
DPS:2.10634 
DPR:0.657  
PE_RATIO:16.4
14 
ASSET:104157.6
979 
MPS:1798.071 
ROE:26.60% 
EPS:1.8849 
DPS:1.7922 
DPR:0.951  
PE_RATIO:953.9
34 
ASSET:20445.919
42 
2013 MPS:24.5025 
ROE:16.55% 
EPS:0.0242 
DPS:0.00605 
DPR:0.250  
PE_RATIO:1012.
500 
ASSET:64.6745 
MPS:112.79439 
ROE:17.13% 
EPS:5.214834 
DPS:1.37997 
DPR:0.265  
PE_RATIO:21.6
30 
ASSET:650.9100
6 
MPS:80.02078 
ROE:21.10% 
EPS:4.072327 
DPS:1.24754 
DPR:0.306
  
PE_RATIO:19.
650 
ASSET:2735.14
234 
MPS:63.44632 
ROE:12.80% 
EPS:2.985185 
DPS:2.183195 
DPR:0.731  
PE_RATIO:21.2
54 
ASSET:100253.1
431 
MPS:2162.5725 
ROE:10.90% 
EPS:0.74415 
DPS:1.02245 
DPR:1.374  
PE_RATIO:2906.
098 
ASSET:20460.431
48 
2014 MPS:23.3965  
ROE:12.35% 
EPS:0.01923 
DPS:0.00641 
DPR:0.333  
PE_RATIO:1216.
667 
ASSET:69.1639 
MPS:126.45465 
ROE:16.06% 
EPS:5.47027 
DPS:1.37845 
DPR:0.252  
PE_RATIO:23.1
17 
ASSET:961.8679 
MPS:78.34464 
ROE:17.68% 
EPS:4.342588 
DPS:1.4838 
DPR:0.342
  
PE_RATIO:18.
041 
ASSET:3173.65
036 
MPS: 91.35262 
ROE:14.07% 
EPS:4.115072 
DPS:2.562028 
DPR:0.623  
PE_RATIO:22.2
00 
ASSET:122693.2
655 
MPS:2911.7425 
ROE:5.80% 
EPS:0.402548 
DPS:1.14739 
DPR:2.850  
PE_RATIO:7233.
280 
ASSET:24075.572 
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2015 MPS:29.025 
ROE:10.85% 
EPS:0.03375 
DPS:0.00675 
DPR:0.200  
PE_RATIO:860.0
00 
ASSET:190.755 
MPS:201.79838 
ROE:2.16% 
EPS:1.028272 
DPS:0 
DPR:0.000  
PE_RATIO:196.
250 
ASSET:1313.433
86 
MPS:156.40838 
ROE:16.80% 
EPS:4.620705 
DPS:1.78866 
DPR:0.387
  
PE_RATIO:33.
84 
ASSET:3617.06
8 
MPS:86.25316 
ROE:24.06% 
EPS:7.303695 
DPS:2.663116 
DPR:0.365  
PE_RATIO:11.8
10 
ASSET:129903.6
08 
MPS:3116.1375 
ROE:14.80% 
EPS:1.0125 
DPS:1.27575 
DPR:1.260  
PE_RATIO:3077.
667 
ASSET:27363.015 
2016 MPS:38.51181 
ROE:10.60% 
EPS:0.03252 
DPS:0.00813 
DPR:0.250  
PE_RATIO:1184.
250 
ASSET:260.7291 
MPS:158.3384 
ROE:7.58% 
EPS:3.89217 
DPS:0 
DPR:0.000  
PE_RATIO:40.6
81 
ASSET:1342.088
4 
MPS:116.94522 
ROE:11.68% 
EPS:3.725148 
DPS:2.0356 
DPR:0.546
  
PE_RATIO:31.
393 
ASSET:5523.70
238 
MPS:75.41898 
ROE:8.80% 
EPS:2.890552 
DPS:2.788772 
DPR:0.965  
PE_RATIO:26.0
92 
ASSET:134691.6
826 
MPS:3607.6875 
ROE:21.00% 
EPS:1.82925 
DPS:1.78047  
DPR:0.973  
PE_RATIO:1972.
222 
ASSET:41327.747 
2017 MPS:49.6688 
ROE:15.10% 
EPS:0.0444 
DPS:0.0074 
DPR:0.167  
PE_RATIO:1118.
667 
ASSET:249.01 
MPS:103.0237 
ROE:-0.57% 
EPS:-0.258602 
DPS:0 
DPR:0.000  
PE_RATIO:-
398.387 
ASSET:1065.523
66 
MPS:121.83995 
ROE:44.20% 
EPS:17.26635 
DPS:1.951 
DPR:0.113
  
PE_RATIO:7.0
56 
ASSET:4024.81
545 
MPS:80.3812 
ROE:10.33% 
EPS:3.111845 
DPS:2.721645 
DPR:0.875  
PE_RATIO:25.8
31 
ASSET:126638.0
053 
MPS:3789.54 
ROE:15.99% 
EPS:1.295 
DPS:1.4948 
DPR:1.154  
PE_RATIO:2926.
286 
ASSET:34692.650
4 
 
 
 
 
 
 
 
GDP Growth 
Rate 
(Year) 
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
India  3.9% 8.5% 10.3%  6.6%  5.5 % 6.4%  7.4%  8.2%  7.1%  6.7%  
USA -
0.3%  
-
2.8%  
2.5%  1.6%  2.2%  1.7%  2.6%  2.9%  1.5%  2.3%  
U K  -
0.5%  
-
4.2%  
1.7%  1.5%  1.5%  2.1%  3.1%  2.3%  1.9%  1.8%  
Germany 0.8%  -
5.6%  
3.9%  3.7%  0.7%  0.6%  1.9%  1.5%  1.9%  2.5%  
France 0.2%  -
2.9%  
2.0%  2.1%  0.2%  0.6%  0.9%  1.1%  1.2%  1.8%  
Switzerland 2.1%  -
2.2%  
2.9%  1.8%  1.00%  1.9%  2.5%  1.2%  1.4%  1.1%  
 
      Key Macroeconomic Data of Selected Countries (GDP) 
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Inflation 
(Year) 
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
India  9.1% 11.0% 9.5% 9.5% 10.0% 9.4% 5.8% 4.9% 4.5% 3.6% 
USA 3.8% -0.3% 1.6% 3.1% 2.1% 1.5% 1.6% 0.1% 1.3% 2.1% 
U K  3.6% 2.2% 3.3% 4.5% 2.8% 2.6% 1.5% 0.0% 0.7% 2.7% 
Germany 2.7% 0.2% 1.2% 2.5% 2.1% 1.6% 0.8% 0.1% 0.4% 1.7% 
France 3.2% 0.1% 1.7% 2.3% 2.2% 1.0% 0.6% 0.1% 0.3% 1.2% 
Switzerland 2.4% -0.5% 0.7% 0.2% -0.7% -0.2% 0.0% -1.1% -0.4% 0.5% 
Key Macroeconomic Data of Selected Countries (Inflation) 
 
Interest 
Rate 
(Year) 
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
India  7.33
% 
5.25% 5.62
% 
7.53% 8.00% 7.55% 8.00% 7.31% 6.37% 6.00
% 
USA 1.79
% 
0.25% 0.25
% 
0.25% 0.25% 0.25% 0.25% 0.375
% 
0.625
% 
1.12
% 
U K  3.95
% 
1.00% 0.5% 0.5% 0.5% 0.50% 0.50% 0.50% 0.37% 0.50
% 
Germany 3.16
% 
1.43% 1.00
% 
1.25% 0.875
% 
0.375
% 
0.10% 0.05% 0.025
% 
0.00
% 
France 3.16
% 
1.43% 1.00
% 
1.25% 0.87% 0.5% 0.15% 0.05% 0.025
% 
0.00
% 
Switzerlan
d 
1.56
% 
0.375
% 
0.25
% 
0.125
% 
0.00% 0.00% -
0.125
% 
-
0.75% 
-
0.75% 
-
0.75
% 
Key Macroeconomic Data of Selected Countries (Interest Rate) 
 
 
Corporate 
Tax 
(Year) 
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
India  33.99
% 
33.99
% 
33.99
% 
32.44
% 
32.45
% 
33.99
% 
33.99
% 
34.61
% 
34.61
% 
34.61
% 
USA 35% 35% 35% 35% 35% 35% 35% 35% 35% 35% 
U K  30% 28% 28% 26% 24% 23% 21% 20% 20% 19% 
Germany 29.5% 29.4% 29.4% 29.4% 29.5% 29.6% 29.6% 29.65
% 
29.72
% 
29.79
% 
France 33.3% 33.3% 33.3% 33.3% 33.3% 33.3% 33.3% 33.3% 33.3% 33.3% 
Switzerlan
d 
19.20
% 
18.96
% 
18.75
% 
18.31
% 
18.06
% 
18.01
% 
17.92
% 
17.92
% 
17.92
% 
17.77
% 
Key Macroeconomic Data of Selected Countries (Corporate Tax) 
 
 
Country Year (April-March) 
Indian Rupee exchange rate against one $ USD 
 
INDIA 
2007-
2008 
2008-
2009 
2009-
2010 
2010-
2011 
2011-
2012 
2012-
2013 
2013-
2014 
2014-
2015 
2015-
2016 
2016-
2017 
39.94 45.90 47.35 45.53 47.90 54.38 60.45 61.13 65.17 67.03 
Key Macroeconomic Data of Selected Countries (Exchange Rate) 
https://www.poundsterlinglive.com 
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Country 
Year (January –December) 
Exchange rate against one $ USD  
2008 2009 2010 2011 2012 2013  2014 2015 2016 2017 
USA 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
United 
Kingdom 
0.695 0.619 0.638 0.646 0.618 0.605 0.641 0.675 0.813 0.74 
Germany 0.7194 0.697 0.7454 0.7729 0.7585 0.7263 0.7255 0.9181 0.947 0.8342 
France 0.7194 0.697 0.7454 0.7729 0.7585 0.7263 0.7255 0.9181 0.947 0.8342 
Switzerland 1.0641 1.0336 0.9321 0.9401 0.9158 0.8911 0.9892 0.9937 1.0178 0.9755 
Key Macroeconomic Data of Selected Countries (Exchange Rate) 
https://www.poundsterlinglive.com 
 
